Molecular	O
Probing	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
Protein	I-GP
Alpha	O
Helix	O
Binding	O
Groove	O
with	O
Small	O
Molecule	O
Inhibitors	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
AR	O
MD	O
VJD	O
EJA	O
.	O

Performed	O
the	O
experiments	O
:	O
AR	O
MD	O
DPP	O
MB	O
.	O

Analyzed	O
the	O
data	O
:	O
AR	O
MD	O
DPP	O
MB	O
VJD	O
EA	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
VJD	O
EJA	O
.	O

Wrote	O
the	O
paper	O
:	O
AR	O
DPP	O
MB	O
MD	O
VJD	O
EJA	O
.	O

The	O
human	B-OG
papillomavirus	I-OG
(	O
HPV	B-OG
)	O
HPV	B-OG
E6	B-GP
protein	I-GP
has	O
emerged	O
as	O
a	O
central	O
oncoprotein	B-GP
in	O
HPV	B-OG
-	O
associated	O
cancers	B-DS
in	O
which	O
sustained	O
expression	O
is	O
required	O
for	O
tumor	B-DS
progression	O
.	O

A	O
majority	O
of	O
the	O
E6	B-GP
protein	I-GP
interactions	O
within	O
the	O
human	B-OG
proteome	O
use	O
an	O
alpha	O
-	O
helix	O
groove	O
interface	O
for	O
binding	O
.	O

The	O
UBE3A	B-GP
/	O
E6AP	B-GP
HECT	O
domain	O
ubiquitin	B-GP
ligase	I-GP
binds	O
E6	B-GP
at	O
this	O
helix	O
-	O
groove	O
interface	O
.	O

This	O
enables	O
formation	O
of	O
a	O
trimeric	O
complex	O
with	O
p53	B-GP
,	O
resulting	O
in	O
destruction	O
of	O
this	O
tumor	B-GP
suppressor	I-GP
.	O

While	O
recent	O
x	O
-	O
ray	O
crystal	O
structures	O
are	O
useful	O
,	O
examples	O
of	O
small	O
molecule	O
probes	O
that	O
can	O
modulate	O
protein	O
interactions	O
at	O
this	O
interface	O
are	O
limited	O
.	O

To	O
develop	O
insights	O
useful	O
for	O
potential	O
structure	O
-	O
based	O
design	O
of	O
ligands	O
for	O
HPV	B-OG
E6	B-GP
,	O
a	O
series	O
of	O
2	O
,	O
6	O
-	O
disubstituted	O
benzopyranones	O
were	O
prepared	O
and	O
tested	O
as	O
competitive	O
antagonists	O
of	O
E6	B-GP
-	O
E6AP	B-GP
helix	O
-	O
groove	O
interactions	O
.	O

These	O
small	O
molecule	O
probes	O
were	O
used	O
in	O
both	O
binding	O
and	O
functional	O
assays	O
to	O
evaluate	O
recognition	O
features	O
of	O
the	O
E6	B-GP
protein	I-GP
.	O

Evidence	O
for	O
an	O
ionic	O
functional	O
group	O
interaction	O
within	O
the	O
helix	O
groove	O
was	O
implicated	O
by	O
the	O
structure	O
-	O
activity	O
among	O
the	O
highest	O
affinity	O
ligands	O
.	O

The	O
molecular	O
topographies	O
of	O
these	O
protein	O
-	O
ligand	O
interactions	O
were	O
evaluated	O
by	O
comparing	O
the	O
binding	O
and	O
activities	O
of	O
single	O
amino	O
acid	O
E6	B-GP
mutants	O
with	O
the	O
results	O
of	O
molecular	O
dynamic	O
simulations	O
.	O

A	O
group	O
of	O
arginine	O
residues	O
that	O
form	O
a	O
rim	O
-	O
cap	O
over	O
the	O
E6	B-GP
helix	O
groove	O
offer	O
compensatory	O
roles	O
in	O
binding	O
and	O
recognition	O
of	O
the	O
small	O
molecule	O
probes	O
.	O

The	O
flexibility	O
and	O
impact	O
on	O
the	O
overall	O
helix	O
-	O
groove	O
shape	O
dictated	O
by	O
these	O
residues	O
offer	O
new	O
insights	O
for	O
structure	O
-	O
based	O
targeting	O
of	O
HPV	B-OG
E6	B-GP
.	O

Introduction	O

There	O
is	O
no	O
effective	O
medical	O
therapy	O
for	O
women	O
and	O
men	O
infected	O
with	O
human	B-OG
papillomavirus	I-OG
(	O
HPV	B-OG
).	O

Persistent	B-DS
infection	I-DS
with	O
specific	O
HPV	B-OG
types	O
carries	O
a	O
high	O
risk	O
of	O
progression	O
from	O
pre	O
-	O
malignant	O
to	O
invasive	O
and	O
metastatic	O
cervical	O
,	O
anogenital	O
and	O
oropharyngeal	B-DS
cancers	I-DS
[	O
1	O
,	O
2	O
].	O

The	O
prototype	O
HPV	B-OG
associated	O
with	O
“	O
high	O
-	O
risk	O
”	O
of	O
neoplastic	O
transformation	O
is	O
HPV	B-OG
-	I-OG
16	I-OG
,	O
which	O
accounts	O
for	O
~	O
50	O
%	O
of	O
all	O
cervical	B-DS
cancers	I-DS
across	O
the	O
world	O
[	O
3	O
,	O
4	O
].	O

The	O
HPV	B-OG
E6	B-GP
protein	I-GP
is	O
essential	O
for	O
viral	O
replication	O
and	O
instrumental	O
in	O
bypassing	O
host	O
cell	O
defenses	O
and	O
preventing	O
apoptosis	O
[	O
5	O
,	O
6	O
].	O

The	O
high	O
risk	O
E6	B-GP
protein	I-GP
binds	O
to	O
the	O
HECT	O
domain	O
ubiquitin	B-GP
ligase	I-GP
,	O
E6AP	B-GP
/	O
UBE3A	B-GP
and	O
this	O
complex	O
is	O
responsible	O
for	O
ubiquitinylation	O
of	O
the	O
p53	B-GP
protein	O
,	O
a	O
major	O
suppressor	O
of	O
tumorigenesis	O
,	O
resulting	O
in	O
its	O
degradation	O
by	O
the	O
cellular	O
proteasome	O
[	O
7	O
,	O
8	O
].	O

This	O
effect	O
can	O
be	O
reversed	O
in	O
HPV	B-OG
-	O
driven	O
tumor	B-DS
cells	O
by	O
reduced	O
expression	O
of	O
HPV	B-OG
E6	B-GP
,	O
which	O
reactivates	O
p53	B-GP
expression	O
and	O
leads	O
to	O
senescence	O
or	O
apoptosis	O
[	O
9	O
–	O
11	O
].	O

Additional	O
cellular	O
factors	O
interact	O
with	O
HPV	B-OG
E6	B-GP
and	O
may	O
be	O
targeted	O
for	O
degradation	O
[	O
12	O
,	O
13	O
].	O

These	O
significant	O
activities	O
make	O
E6	B-GP
a	O
compelling	O
target	O
for	O
the	O
treatment	O
of	O
HPV	B-DS
-	I-DS
associated	I-DS
infections	I-DS
.	O

Peptide	O
ligands	O
for	O
the	O
E6	B-GP
hydrophobic	O
groove	O
that	O
were	O
derived	O
from	O
the	O
alpha	O
-	O
helical	O
LXXLL	O
motif	O
of	O
E6AP	B-GP
have	O
been	O
characterized	O
previously	O
.	O

While	O
comparatively	O
low	O
in	O
binding	O
affinities	O
,	O
these	O
peptides	O
are	O
able	O
to	O
disturb	O
E6	B-GP
/	O
E6AP	B-GP
interaction	O
[	O
14	O
,	O
15	O
].	O

A	O
chimeric	O
protein	O
that	O
contains	O
the	O
LXXLL	O
motif	O
and	O
the	O
PDZ	O
motif	O
displays	O
much	O
higher	O
binding	O
affinity	O
when	O
compared	O
to	O
the	O
LXXLL	O
motif	O
alone	O
[	O
16	O
,	O
17	O
].	O

Interestingly	O
,	O
a	O
novel	O
small	O
peptide	O
unrelated	O
to	O
the	O
E6AP	B-GP
binding	O
motif	O
,	O
also	O
inhibits	O
E6	B-GP
function	O
by	O
blocking	O
the	O
interaction	O
of	O
E6	B-GP
with	O
E6AP	B-GP
[	O
18	O
,	O
19	O
].	O

Additional	O
peptide	O
-	O
based	O
protein	O
-	O
protein	O
interaction	O
inhibitors	O
(	O
PPI	O
)	O
have	O
achieved	O
some	O
partial	O
successes	O
[	O
20	O
,	O
21	O
].	O

The	O
LXXLL	O
containing	O
alpha	O
-	O
helix	O
binds	O
in	O
a	O
hydrophobic	O
pocket	O
of	O
E6	B-GP
[	O
22	O
].	O

In	O
this	O
regard	O
,	O
the	O
specific	O
interface	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP
with	O
E6AP	B-GP
and	O
its	O
other	O
LXXLL	O
binding	O
partners	O
presents	O
significant	O
opportunities	O
for	O
targeting	O
with	O
small	O
molecules	O
(	O
Fig	O
1	O
).	O

Despite	O
the	O
large	O
overall	O
surface	O
area	O
(	O
902	O
–	O
1005	O
Å	O
)	O
for	O
the	O
groove	O
,	O
we	O
and	O
others	O
have	O
previously	O
identified	O
flavonoid	O
derived	O
compounds	O
as	O
E6	B-GP
inhibitory	O
compounds	O
[	O
23	O
–	O
27	O
].	O

A	O
limited	O
structure	O
-	O
activity	O
study	O
identified	O
a	O
tetrazole	O
-	O
substituted	O
benzopyranone	O
analog	O
that	O
antagonized	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
in	O
vitro	O
and	O
had	O
effective	O
IC50	O
values	O
in	O
the	O
lower	O
micromolar	O
range	O
[	O
25	O
].	O

Initial	O
molecular	O
modeling	O
studies	O
showed	O
that	O
these	O
compounds	O
could	O
bind	O
within	O
the	O
hydrophobic	O
groove	O
of	O
the	O
E6	B-GP
protein	I-GP
that	O
has	O
been	O
shown	O
to	O
contact	O
E6AP	B-GP
[	O
25	O
].	O

The	O
motivation	O
for	O
the	O
current	O
study	O
was	O
to	O
understand	O
the	O
contribution	O
of	O
the	O
2	O
’-	O
6	O
’	O
substitution	O
groups	O
on	O
the	O
benzopyranone	O
scaffold	O
and	O
to	O
determine	O
what	O
features	O
of	O
E6	B-GP
are	O
involved	O
.	O

We	O
observed	O
increased	O
inhibitory	O
activity	O
of	O
small	O
molecules	O
with	O
charged	O
groups	O
at	O
position	O
6	O
as	O
well	O
as	O
a	O
higher	O
activity	O
for	O
compounds	O
with	O
non	O
-	O
polar	O
substituents	O
at	O
the	O
2	O
position	O
.	O

Based	O
on	O
these	O
results	O
,	O
a	O
subset	O
of	O
analogs	O
was	O
selected	O
to	O
probe	O
E6	B-GP
binding	O
interactions	O
.	O

Molecular	O
dynamics	O
simulations	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP
implicated	O
a	O
high	O
degree	O
of	O
flexibility	O
of	O
charged	O
residues	O
along	O
the	O
helix	O
groove	O
that	O
could	O
dominate	O
small	O
molecule	O
interactions	O
.	O

A	O
focused	O
set	O
of	O
mutations	O
at	O
these	O
amino	O
acids	O
revealed	O
important	O
roles	O
in	O
defining	O
the	O
molecular	O
interactions	O
of	O
the	O
E6	B-GP
hydrophobic	O
groove	O
and	O
offered	O
insights	O
for	O
future	O
structure	O
-	O
guided	O
ligand	O
design	O
.	O

The	O
unique	O
topography	O
of	O
the	O
α	O
-	O
helix	O
binding	O
groove	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
is	O
essential	O
in	O
maintaining	O
strong	O
polar	O
contacts	O
with	O
the	O
E6	B-GP
binding	O
motif	O
.	O

The	O
rim	O
arginines	O
R10	O
,	O
R55	O
,	O
R102	O
,	O
R129	O
,	O
and	O
R131	O
form	O
multiple	O
hydrogen	O
bonds	O
with	O
both	O
backbone	O
and	O
side	O
-	O
chain	O
atoms	O
.	O

Other	O
key	O
highlighted	O
residues	O
are	O
K11	O
,	O
and	O
L50	O
,	O
which	O
are	O
proposed	O
to	O
be	O
crucial	O
for	O
maintaining	O
E6	B-GP
shape	O
and	O
activity	O
.	O

Results	O
and	O
Discussion	O

Characterization	O
of	O
MBP	B-GP
-	O
E6	B-GP
proteins	I-GP
and	O
assay	O
validation	O

To	O
confirm	O
the	O
integrity	O
of	O
the	O
purified	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP
,	O
we	O
assessed	O
its	O
in	O
vitro	O
p53	B-GP
degradation	O
activity	O
with	O
respect	O
to	O
time	O
and	O
concentration	O
(	O
Fig	O
2A	O
and	O
2B	O
).	O

The	O
observed	O
MBP	B-GP
-	O
E6	B-GP
in	O
vitro	O
p53	B-GP
degradation	O
activity	O
was	O
comparable	O
to	O
that	O
observed	O
for	O
a	O
mutant	O
MBP	B-GP
-	O
E6	B-GP
in	O
which	O
six	O
or	O
four	O
(	O
bold	O
)	O
cysteines	O
(	O
C16	O
,	O
C51	O
,	O
C80	O
,	O
C97	O
,	O
C111	O
,	O
C140	O
)	O
were	O
all	O
replaced	O
with	O
serines	O
[	O
28	O
,	O
29	O
].	O

The	O
binding	O
capacity	O
of	O
MBP	B-GP
-	O
E6	B-GP
for	O
the	O
E6AP	B-GP
-	O
BAP	B-GP
fusion	O
protein	O
was	O
tested	O
using	O
analogous	O
conditions	O
previously	O
established	O
for	O
GST	B-GP
-	O
E6	B-GP
[	O
8	O
,	O
25	O
,	O
30	O
].	O

For	O
this	O
comparison	O
,	O
MBP	B-GP
protein	O
alone	O
and	O
two	O
mutated	O
MBP	B-GP
-	O
E6	B-GP
fusion	O
proteins	O
were	O
included	O
.	O

E6	B-GP
L50G	O
,	O
a	O
point	O
mutation	O
that	O
disables	O
binding	O
to	O
E6AP	B-GP
and	O
p53	B-GP
[	O
30	O
,	O
31	O
],	O
and	O
E6	B-GP
F2V	O
,	O
which	O
diminishes	O
binding	O
to	O
p53	B-GP
but	O
retains	O
partial	O
binding	O
to	O
E6AP	B-GP
[	O
30	O
,	O
32	O
],	O
served	O
as	O
controls	O
(	O
Fig	O
2C	O
).	O

MBP	B-GP
-	O
E6	B-GP
F2V	O
retained	O
~	O
70	O
%	O
of	O
the	O
wild	O
-	O
type	O
binding	O
capacity	O
,	O
while	O
MBP	B-GP
and	O
MBP	B-GP
-	O
E6	B-GP
L50G	O
showed	O
no	O
significant	O
binding	O
to	O
E6AP	B-GP
.	O

Neither	O
MBP	B-GP
-	O
E6	B-GP
L50G	O
,	O
nor	O
F2V	O
induced	O
degradation	O
of	O
p53	B-GP
at	O
the	O
concentrations	O
studied	O
(	O
Fig	O
2D	O
).	O

Characterization	O
of	O
wild	O
-	O
type	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
.	O

(	O
A	O
)	O
Time	O
course	O
and	O
(	O
B	O
)	O
Dose	O
response	O
of	O
MBP	B-GP
-	O
E6	B-GP
mediated	O
p53	B-GP
in	O
vitro	O
degradation	O
activity	O
.	O

(	O
C	O
)	O
Binding	O
capacity	O
of	O
wild	O
-	O
type	O
E6	B-GP
and	O
mutants	O
F2V	O
and	O
L50G	O
to	O
E6AP	B-GP
in	O
the	O
bead	O
-	O
based	O
assay	O
.	O

(	O
D	O
)	O
p53	B-GP
in	O
vitro	O
degradation	O
with	O
F2V	O
and	O
L50G	O
.	O

(	O
E	O
,	O
F	O
)	O
Thermal	O
stability	O
profiles	O
of	O
MBP	B-GP
,	O
MBP	B-GP
-	O
E6	B-GP
and	O
MBP	B-GP
-	O
E6	B-GP
L50G	O
.	O

All	O
data	O
are	O
expressed	O
as	O
S	O
.	O
E	O
.	O
M	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

A	O
second	O
binding	O
assay	O
was	O
employed	O
based	O
upon	O
MBP	B-GP
-	O
E6	B-GP
unfolding	O
in	O
the	O
Sypro	O
Orange	O
-	O
based	O
thermal	O
stability	O
assay	O
(	O
TSA	O
)	O
[	O
25	O
,	O
33	O
].	O

Purified	O
MBP	B-GP
protein	O
denaturation	O
showed	O
a	O
Tm	O
of	O
59	O
.	O
7	O
±	O
0	O
.	O
1	O
°	O
C	O
,	O
which	O
is	O
comparable	O
to	O
wild	O
-	O
type	O
MBP	B-GP
protein	O
(	O
62	O
.	O
3	O
°	O
C	O
;	O
pH	O
8	O
.	O
2	O
[	O
34	O
]).	O

The	O
slight	O
difference	O
in	O
our	O
assay	O
(	O
pH	O
6	O
.	O
8	O
)	O
is	O
due	O
to	O
the	O
reported	O
pH	O
sensitivity	O
of	O
MBP	B-GP
[	O
34	O
].	O

MBP	B-GP
-	O
E6	B-GP
fusion	O
proteins	O
displayed	O
increased	O
basal	O
fluorescence	O
compared	O
to	O
MBP	B-GP
alone	O
,	O
implying	O
that	O
MBP	B-GP
does	O
not	O
limit	O
accessibility	O
of	O
the	O
E6	B-GP
protein	I-GP
to	O
Sypro	O
Orange	O
(	O
Fig	O
2E	O
).	O

Analysis	O
of	O
thermal	O
stability	O
of	O
fusion	O
-	O
proteins	O
could	O
result	O
in	O
two	O
melt	O
peaks	O
from	O
unfolding	O
of	O
the	O
MBP	B-GP
and	O
E6	B-GP
domains	O
.	O

Only	O
a	O
single	O
peak	O
was	O
observed	O
with	O
MBP	B-GP
-	O
E6	B-GP
that	O
is	O
consistent	O
with	O
a	O
predicted	O
Tm	O
between	O
55	O
–	O
65	O
°	O
C	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
(	O
Fig	O
2F	O
;	O
MBP	B-GP
-	O
E6	B-GP
Tm	O
:	O
58	O
.	O
2	O
±	O
0	O
.	O
1	O
°	O
C	O
).	O

The	O
melting	O
temperature	O
of	O
purified	O
wild	O
-	O
type	O
E6	B-GP
alone	O
is	O
difficult	O
to	O
assess	O
due	O
to	O
its	O
aggregation	O
-	O
prone	O
nature	O
[	O
35	O
,	O
36	O
].	O

However	O
,	O
an	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
mutant	O
protein	O
,	O
in	O
which	O
all	O
nine	O
cysteines	O
were	O
converted	O
to	O
residues	O
found	O
in	O
HPV	B-OG
-	I-OG
1A	I-OG
,	O
had	O
a	O
Tm	O
of	O
~	O
60	O
°	O
C	O
[	O
27	O
].	O

Inhibitory	O
compounds	O
bind	O
to	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP

Previously	O
,	O
a	O
series	O
of	O
carboxylate	O
-	O
and	O
tetrazole	O
-	O
substituted	O
benzopyranones	O
were	O
reported	O
to	O
inhibit	O
the	O
E6	B-GP
-	O
E6AP	B-GP
peptide	O
interactions	O
[	O
25	O
].	O

The	O
roles	O
and	O
contributions	O
of	O
the	O
2	O
–	O
6	O
functional	O
groups	O
on	O
the	O
benzopyranone	O
core	O
were	O
investigated	O
to	O
gain	O
insight	O
regarding	O
the	O
potential	O
sites	O
of	O
interactions	O
with	O
HPV	B-OG
E6	B-GP
.	O

Compounds	O
CAF	O
-	O
24	O
,	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
26	O
displayed	O
similar	O
apparent	O
binding	O
with	O
the	O
E6AP	B-GP
displacement	O
assay	O
using	O
MBP	B-GP
-	O
E6	B-GP
fusion	O
proteins	O
(	O
Fig	O
3A	O
,	O
Fig	O
4	O
)	O
[	O
25	O
].	O

To	O
further	O
establish	O
the	O
TSA	O
as	O
a	O
means	O
to	O
measure	O
direct	O
compound	O
binding	O
to	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
,	O
we	O
first	O
determined	O
the	O
MBP	B-GP
and	O
MBP	B-GP
-	O
16	O
E6	B-GP
melt	O
curves	O
in	O
response	O
to	O
increasing	O
doses	O
of	O
maltose	O
(	O
Fig	O
3B	O
).	O

We	O
observed	O
similar	O
ΔTm	O
changes	O
in	O
response	O
to	O
maltose	O
with	O
both	O
proteins	O
,	O
indicating	O
comparable	O
accessibility	O
of	O
the	O
MBP	B-GP
tag	O
(	O
Fig	O
3C	O
).	O

The	O
E6	B-GP
inhibitor	O
CAF	O
-	O
25	O
stabilized	O
purified	O
MBP	B-GP
-	O
E6	B-GP
in	O
a	O
saturation	O
-	O
dependent	O
manner	O
(	O
Fig	O
3D	O
–	O
3G	O
and	O
Fig	O
4	O
).	O

MBP	B-GP
itself	O
was	O
either	O
not	O
affected	O
or	O
destabilized	O
with	O
these	O
compounds	O
,	O
providing	O
evidence	O
for	O
selective	O
binding	O
to	O
the	O
E6	B-GP
protein	I-GP
.	O

The	O
destabilizing	O
effect	O
on	O
MBP	B-GP
protein	O
may	O
contribute	O
to	O
the	O
smaller	O
global	O
ΔTm	O
changes	O
detected	O
with	O
these	O
compounds	O
and	O
MBP	B-GP
-	O
E6	B-GP
protein	I-GP
.	O

In	O
addition	O
,	O
the	O
relatively	O
large	O
MBP	B-GP
-	O
tag	O
could	O
mask	O
true	O
ΔTm	O
changes	O
upon	O
compound	O
binding	O
to	O
the	O
relatively	O
small	O
E6	B-GP
protein	I-GP
.	O

We	O
observed	O
that	O
at	O
150	O
μM	O
,	O
some	O
of	O
the	O
E6	B-GP
inhibitors	O
quenched	O
the	O
melt	O
curve	O
,	O
hence	O
we	O
chose	O
to	O
compare	O
the	O
ΔTm	O
changes	O
at	O
50	O
μM	O
(	O
Fig	O
4	O
).	O

Compounds	O
that	O
performed	O
consistently	O
in	O
the	O
binding	O
and	O
TSA	O
assays	O
were	O
investigated	O
using	O
the	O
p53	B-GP
in	O
vitro	O
degradation	O
assay	O
(	O
Fig	O
3H	O
;	O
S1A	O
Fig	O
;	O
and	O
Fig	O
4	O
).	O

Compounds	O
CAF	O
-	O
24	O
,	O
-	O
25	O
,	O
-	O
26	O
and	O
CAF	O
-	O
40	O
showed	O
similar	O
efficiencies	O
in	O
the	O
binding	O
and	O
functional	O
E6	B-GP
mediated	O
p53	B-GP
degradation	O
assays	O
,	O
while	O
CAF	O
-	O
27	O
exhibited	O
lower	O
than	O
expected	O
efficiency	O
.	O

This	O
may	O
be	O
due	O
to	O
lower	O
binding	O
affinity	O
as	O
indicated	O
by	O
the	O
smaller	O
ΔTm	O
changes	O
.	O

Compounds	O
with	O
a	O
tetrazole	O
group	O
in	O
the	O
6	O
'	O
position	O
of	O
the	O
benzopyranone	O
core	O
showed	O
enhanced	O
selectivity	O
for	O
the	O
E6	B-GP
protein	I-GP
when	O
compared	O
with	O
the	O
benzoate	O
functional	O
group	O
at	O
the	O
same	O
position	O
.	O

There	O
also	O
appears	O
to	O
be	O
preference	O
for	O
non	O
-	O
polar	O
substituent	O
in	O
positions	O
3	O
and	O
4	O
of	O
2	O
-	O
aryl	O
group	O
.	O

While	O
unsaturated	O
ketones	O
are	O
prone	O
to	O
be	O
pan	O
assay	O
interference	O
(	O
PAINS	O
)	O
compounds	O
[	O
37	O
,	O
38	O
],	O
we	O
believe	O
that	O
the	O
observed	O
interaction	O
of	O
tetrazole	O
-	O
based	O
flavone	O
compounds	O
with	O
E6	B-GP
shows	O
specificity	O
based	O
on	O
the	O
following	O
evidence	O
.	O

Probes	O
did	O
not	O
1	O
)	O
inhibit	O
the	O
binding	O
of	O
FLAG	O
beads	O
to	O
FLAG	O
-	O
tagged	O
E6AP	B-GP
-	O
BAP	B-GP
peptide	O
,	O
indicating	O
no	O
interference	O
with	O
BAP	B-GP
activity	O
itself	O
or	O
interference	O
of	O
antibody	B-GP
recognition	O
of	O
the	O
fusion	O
protein	O
,	O
2	O
)	O
inhibit	O
interaction	O
of	O
hDLG	B-GP
with	O
E6AP	B-GP
-	O
BAP	B-GP
peptide	O
[	O
25	O
],	O
or	O
3	O
)	O
stabilize	O
MBP	B-GP
protein	O
in	O
the	O
TSA	O
.	O

In	O
addition	O
,	O
the	O
binding	O
assay	O
contains	O
0	O
.	O
1	O
%	O
milk	O
to	O
reduce	O
non	O
-	O
specific	O
interactions	O
.	O

While	O
other	O
off	O
-	O
target	O
effects	O
cannot	O
be	O
excluded	O
,	O
these	O
results	O
motivated	O
the	O
question	O
of	O
what	O
key	O
recognition	O
features	O
of	O
the	O
E6	B-GP
protein	I-GP
are	O
being	O
exploited	O
by	O
these	O
substitutions	O
.	O

Molecular	O
docking	O
of	O
the	O
2	O
–	O
6	O
substituted	O
benzopyranone	O
indicated	O
a	O
minimal	O
set	O
of	O
poses	O
and	O
implicate	O
direct	O
hydrophobic	O
groove	O
binding	O
on	O
E6	B-GP
.	O

However	O
,	O
molecular	O
docking	O
analysis	O
using	O
Glide	O
Induced	O
-	O
Fit	O
scores	O
did	O
not	O
correlate	O
with	O
experimental	O
results	O
(	O
data	O
not	O
shown	O
).	O

CAF	O
-	O
25	O
binding	O
to	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
.	O

(	O
A	O
)	O
Dose	O
response	O
effect	O
of	O
CAF	O
-	O
25	O
on	O
MBP	B-GP
-	O
E6	B-GP
/	O
E6AP	B-GP
binding	O
in	O
the	O
bead	O
-	O
based	O
assay	O
.	O

(	O
B	O
)	O
Effect	O
of	O
maltose	O
on	O
MBP	B-GP
melt	O
curve	O
in	O
the	O
TSA	O
.	O

(	O
C	O
)	O
Dose	O
dependent	O
effect	O
of	O
maltose	O
on	O
the	O
melting	O
temperature	O
changes	O
(	O
ΔTM	O
)	O
on	O
MBP	B-GP
and	O
MBP	B-GP
-	O
E6	B-GP
.	O

(	O
D	O
)	O
Raw	O
fluorescence	O
plot	O
of	O
MBP	B-GP
-	O
E6	B-GP
melt	O
curves	O
in	O
response	O
to	O
increasing	O
CAF	O
-	O
25	O
.	O

Relative	O
fluorescence	O
plots	O
of	O
MBP	B-GP
-	O
E6	B-GP
(	O
E	O
)	O
and	O
MBP	B-GP
(	O
F	O
)	O
melt	O
curves	O
in	O
response	O
to	O
CAF	O
-	O
25	O
.	O

Negative	O
control	O
is	O
composed	O
of	O
Sypro	O
Orange	O
in	O
buffer	O
.	O

(	O
G	O
)	O
Summary	O
of	O
the	O
ΔTM	O
changes	O
of	O
MBP	B-GP
and	O
MBP	B-GP
-	O
E6	B-GP
by	O
CAF	O
-	O
25	O
.	O

(	O
H	O
)	O
Inhibition	O
of	O
MBP	B-GP
-	O
E6	B-GP
mediated	O
p53	B-GP
degradation	O
by	O
CAF	O
-	O
25	O
.	O

All	O
data	O
are	O
expressed	O
as	O
S	O
.	O
E	O
.	O
M	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

Interactions	O
of	O
2	O
and	O
6	O
substituted	O
benzopyranone	O
analogs	O
with	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
.	O

IC50	O
and	O
maximal	O
inhibition	O
determined	O
in	O
the	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
/	O
E6AP	B-GP
binding	O
assay	O
;	O
ΔTM	O
change	O
of	O
MBP	B-GP
-	O
E6	B-GP
and	O
MBP	B-GP
at	O
50	O
μM	O
compound	O
over	O
DMSO	O
control	O
in	O
the	O
TSA	O
;	O
TSA	O
MBP	B-GP
-	O
E6	B-GP
—	O
apparent	O
Kd	O
of	O
compound	O
interaction	O
;	O
IC50	O
in	O
the	O
p53	B-GP
in	O
vitro	O
degradation	O
assay	O
with	O
MBP	B-GP
-	O
E6	B-GP
.	O

N	O
.	O
d	O
.	O
not	O
determined	O
.	O

Molecular	O
Dynamics	O
simulations	O

The	O
observed	O
differences	O
between	O
experimental	O
data	O
and	O
in	O
silico	O
docking	O
results	O
motivated	O
an	O
alternative	O
approach	O
to	O
assess	O
compound	O
binding	O
to	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
using	O
molecular	O
dynamics	O
simulations	O
.	O

CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
were	O
chosen	O
for	O
computational	O
modeling	O
as	O
representative	O
of	O
the	O
tetrazole	O
and	O
non	O
-	O
tetrazole	O
classes	O
,	O
respectively	O
.	O

Each	O
have	O
the	O
lowest	O
IC50	O
values	O
in	O
the	O
respective	O
classes	O
,	O
and	O
CAF	O
-	O
40	O
features	O
an	O
alkyne	O
moiety	O
with	O
additional	O
carbons	O
at	O
the	O
position	O
2	O
'	O
of	O
the	O
benzopyranone	O
core	O
,	O
allowing	O
it	O
to	O
explore	O
a	O
potentially	O
different	O
and	O
larger	O
area	O
of	O
the	O
binding	O
pocket	O
.	O

Over	O
the	O
course	O
of	O
each	O
simulation	O
,	O
it	O
became	O
evident	O
that	O
arginine	O
residues	O
along	O
the	O
periphery	O
of	O
the	O
E6AP	B-GP
binding	O
groove	O
play	O
a	O
substantial	O
role	O
in	O
the	O
non	O
-	O
bonding	O
interactions	O
between	O
the	O
ligands	O
and	O
the	O
protein	O
.	O

We	O
observed	O
a	O
previously	O
unseen	O
flexibility	O
of	O
specific	O
arginine	O
residues	O
that	O
reside	O
on	O
the	O
edges	O
of	O
the	O
hydrophobic	O
pocket	O
(	O
Fig	O
5A	O
,	O
5B	O
and	O
S1C	O
,	O
S1D	O
Fig	O
)	O
and	O
partially	O
define	O
the	O
shape	O
of	O
the	O
groove	O
.	O

The	O
identified	O
interactions	O
of	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
with	O
E6	B-GP
protein	I-GP
(	O
PDB	O
ID	O
:	O
4GIZ	O
)	O
using	O
MD	O
simulations	O
are	O
summarized	O
in	O
Fig	O
5C	O
,	O
5D	O
and	O
S1C	O
,	O
S1D	O
Fig	O
.	O

Arginine	O
102	O
maintained	O
contact	O
with	O
the	O
CAF	O
-	O
25	O
ligand	O
throughout	O
the	O
majority	O
of	O
the	O
simulation	O
time	O
frame	O
(	O
Fig	O
5C	O
),	O
while	O
cysteine	O
C51	O
was	O
found	O
to	O
play	O
a	O
major	O
role	O
by	O
forming	O
a	O
backbone	O
hydrogen	O
bond	O
with	O
the	O
benzopyranone	O
ketone	O
oxygen	O
of	O
CAF	O
-	O
25	O
.	O

The	O
C51	O
residue	O
also	O
maintained	O
contact	O
with	O
CAF	O
-	O
40	O
;	O
however	O
,	O
in	O
this	O
case	O
the	O
ring	O
oxygen	O
of	O
the	O
benzopyranone	O
was	O
involved	O
(	O
Fig	O
5D	O
and	O
S1D	O
Fig	O
).	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
(	O
PDB	O
ID	O
:	O
4GIZ	O
).	O

The	O
five	O
arginine	O
residues	O
surrounding	O
the	O
binding	O
groove	O
are	O
highly	O
flexible	O
(	O
A	O
)	O
and	O
both	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
assume	O
similar	O
docking	O
orientations	O
,	O
maximizing	O
their	O
interactions	O
with	O
R102	O
,	O
R129	O
,	O
and	O
R131	O
(	O
B	O
).	O

Panels	O
C	O
and	O
D	O
show	O
a	O
detailed	O
interaction	O
map	O
with	O
the	O
binding	O
groove	O
of	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
,	O
respectively	O
.	O

In	O
both	O
cases	O
,	O
H	O
-	O
bonding	O
and	O
π	O
-	O
cation	O
contacts	O
with	O
R102	O
,	O
R129	O
,	O
R131	O
,	O
K11	O
,	O
C51	O
,	O
and	O
S74	O
form	O
the	O
primary	O
basis	O
for	O
interaction	O
with	O
E6	B-GP
.	O

Characterization	O
of	O
E6	B-GP
mutants	O

To	O
test	O
the	O
implications	O
from	O
the	O
MD	O
models	O
of	O
compound	O
binding	O
,	O
a	O
series	O
of	O
point	O
mutations	O
of	O
four	O
arginines	O
to	O
alanine	O
(	O
R10A	O
,	O
R55A	O
,	O
R102A	O
,	O
R131A	O
)	O
were	O
prepared	O
.	O

These	O
E6	B-GP
mutant	O
proteins	O
did	O
not	O
bind	O
to	O
E6AP	B-GP
-	O
BAP	B-GP
in	O
the	O
bead	O
based	O
assay	O
at	O
the	O
concentrations	O
studied	O
(	O
Fig	O
6A	O
).	O

Analysis	O
of	O
melting	O
curves	O
indicated	O
that	O
none	O
of	O
the	O
R	O
to	O
A	O
mutant	O
E6	B-GP
proteins	I-GP
appeared	O
to	O
be	O
destabilized	O
relative	O
to	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
(	O
S1E	O
Fig	O
).	O

In	O
contrast	O
,	O
these	O
E6	B-GP
mutants	O
demonstrated	O
significant	O
activity	O
in	O
the	O
p53	B-GP
degradation	O
assay	O
,	O
with	O
R10A	O
and	O
R131A	O
maintaining	O
activities	O
comparable	O
to	O
wild	O
-	O
type	O
MBP	B-GP
-	O
E6	B-GP
(	O
Fig	O
6B	O
).	O

However	O
,	O
R55A	O
was	O
50	O
%	O
as	O
active	O
and	O
R102A	O
was	O
defective	O
at	O
the	O
concentrations	O
studied	O
(	O
Fig	O
6B	O
).	O

These	O
in	O
vitro	O
p53	B-GP
degradation	O
activities	O
are	O
in	O
agreement	O
with	O
previously	O
published	O
results	O
for	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP
containing	O
four	O
cysteine	O
to	O
serine	O
mutations	O
4C4S	O
[	O
39	O
].	O

To	O
clarify	O
whether	O
purified	O
MBP	B-GP
-	O
E6	B-GP
R102A	O
may	O
exert	O
p53	B-GP
degradation	O
activity	O
if	O
allowed	O
to	O
react	O
longer	O
,	O
reactions	O
were	O
incubated	O
for	O
3h	O
at	O
which	O
R102A	O
decreased	O
p53	B-GP
by	O
50	O
%	O
at	O
1	O
μM	O
but	O
not	O
at	O
0	O
.	O
25	O
μM	O
(	O
S1F	O
Fig	O
).	O

Further	O
evaluation	O
of	O
these	O
E6	B-GP
mutants	O
was	O
also	O
investigated	O
using	O
a	O
cell	O
-	O
based	O
assay	O
with	O
a	O
p53	B-GP
-	O
luciferase	B-GP
(	O
p53	B-GP
-	O
luc	B-GP
)	O
reporter	O
construct	O
[	O
40	O
].	O

HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
wild	O
-	O
type	O
decreased	O
levels	O
of	O
the	O
p53	B-GP
-	O
luc	B-GP
protein	O
,	O
while	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
L50G	O
mutant	O
did	O
not	O
in	O
the	O
range	O
of	O
concentrations	O
studied	O
.	O

Similar	O
to	O
in	O
vitro	O
degradation	O
assays	O
,	O
E6	B-GP
mutants	O
R10A	O
and	O
R131A	O
showed	O
activity	O
equivalent	O
to	O
wild	O
-	O
type	O
,	O
while	O
E6	B-GP
R55A	O
gained	O
activity	O
in	O
this	O
assay	O
relative	O
to	O
wild	O
-	O
type	O
.	O

HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
R102A	O
was	O
partially	O
defective	O
in	O
the	O
in	O
vitro	O
assay	O
and	O
also	O
appears	O
partially	O
defective	O
in	O
reducing	O
levels	O
of	O
p53	B-GP
-	O
luc	B-GP
(	O
EC50	O
R102A	O
vs	O
.	O
wild	O
-	O
type	O
:	O
172	O
±	O
43	O
vs	O
.	O
32	O
±	O
2	O
ng	O
;	O
Fig	O
6E	O
).	O

In	O
summary	O
,	O
these	O
results	O
indicate	O
a	O
greater	O
role	O
of	O
R102	O
in	O
the	O
interaction	O
with	O
E6AP	B-GP
than	O
the	O
other	O
arginine	O
residues	O
studied	O
.	O

Notably	O
,	O
R102	O
and	O
R55	O
are	O
conserved	O
in	O
high	O
risk	O
HPV	B-OG
-	I-OG
18	I-OG
E6	B-GP
,	O
which	O
also	O
binds	O
E6AP	B-GP
and	O
induces	O
degradation	O
of	O
p53	B-GP
.	O

The	O
inability	O
to	O
detect	O
E6	B-GP
mutant	O
binding	O
to	O
E6AP	B-GP
-	O
BAP	B-GP
in	O
vitro	O
,	O
while	O
these	O
retained	O
E6AP	B-GP
-	O
dependent	O
p53	B-GP
degradation	O
in	O
vitro	O
and	O
in	O
cells	O
,	O
may	O
reflect	O
the	O
different	O
experimental	O
conditions	O
or	O
a	O
stabilizing	O
contribution	O
of	O
p53	B-GP
in	O
the	O
trimeric	O
complex	O
(	O
E6	B-GP
/	O
E6AP	B-GP
/	O
p53	B-GP
).	O

Characterization	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
arginine	O
mutants	O
.	O

(	O
A	O
)	O
Binding	O
of	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
and	O
mutants	O
R10A	O
,	O
R55A	O
,	O
R102A	O
and	O
R131A	O
to	O
E6AP	B-GP
in	O
the	O
bead	O
-	O
based	O
assay	O
.	O

(	O
B	O
)	O
p53	B-GP
in	O
vitro	O
degradation	O
by	O
wild	O
-	O
type	O
and	O
MBP	B-GP
-	O
E6	B-GP
mutants	O
.	O

Top	O
panel	O
:	O
representative	O
western	O
blots	O
blotted	O
with	O
anti	O
-	O
p53	B-GP
and	O
anti	O
-	O
E6	B-GP
.	O

Bottom	O
panel	O
:	O
Densitometric	O
analysis	O
of	O
p53	B-GP
expressed	O
as	O
fold	O
change	O
over	O
p53	B-GP
control	O
.	O

(	O
C	O
)	O
C33a	O
cells	O
transiently	O
transfected	O
with	O
p53	B-GP
-	O
luc	B-GP
,	O
firefly	B-OG
luciferase	B-GP
and	O
increasing	O
DNA	O
concentrations	O
of	O
16E6	O
and	O
mutants	O
analyzed	O
for	O
luciferase	B-GP
activities	O
at	O
24	O
hrs	O
.	O

All	O
data	O
are	O
expressed	O
as	O
S	O
.	O
E	O
.	O
M	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

Characterization	O
of	O
compound	O
binding	O
to	O
E6	B-GP
mutants	O

The	O
contribution	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
arginine	O
mutations	O
to	O
compound	O
binding	O
was	O
tested	O
in	O
the	O
TSA	O
(	O
Fig	O
7A	O
and	O
7B	O
,	O
S2	O
–	O
S5	O
Figs	O
and	O
S2	O
Table	O
).	O

Compounds	O
CAF	O
-	O
25	O
,	O
CAF	O
-	O
26	O
,	O
CAF	O
-	O
27	O
and	O
CAF	O
-	O
40	O
were	O
chosen	O
as	O
test	O
molecules	O
.	O

The	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
26	O
compounds	O
have	O
close	O
structural	O
similarities	O
except	O
for	O
the	O
CF3	O
group	O
in	O
position	O
3	O
'	O
of	O
the	O
2	O
-	O
aryl	O
group	O
.	O

We	O
included	O
CAF	O
-	O
27	O
and	O
CAF	O
-	O
40	O
as	O
these	O
represent	O
elongated	O
structures	O
,	O
which	O
would	O
occupy	O
a	O
larger	O
volume	O
of	O
the	O
hydrophobic	O
-	O
groove	O
but	O
also	O
engage	O
some	O
ionic	O
features	O
with	O
the	O
tetrazole	O
groups	O
.	O

MD	O
simulations	O
also	O
indicated	O
that	O
the	O
interaction	O
pattern	O
of	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
with	O
E6	B-GP
could	O
be	O
sufficiently	O
different	O
to	O
be	O
distinguished	O
in	O
the	O
TSA	O
.	O

Interaction	O
of	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
26	O
with	O
MBP	B-GP
-	O
E6	B-GP
R131A	O
protein	O
.	O

ΔTM	O
profile	O
of	O
MBP	B-GP
-	O
E6	B-GP
and	O
R131A	O
in	O
response	O
to	O
increasing	O
concentrations	O
of	O
(	O
A	O
)	O
CAF	O
-	O
25	O
and	O
(	O
B	O
)	O
CAF	O
-	O
26	O
.	O

(	O
C	O
)	O
Western	O
blot	O
of	O
the	O
p53	B-GP
in	O
vitro	O
degradation	O
activity	O
of	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
(	O
top	O
)	O
and	O
R131A	O
mutant	O
(	O
bottom	O
)	O
in	O
response	O
to	O
CAF	O
-	O
26	O
.	O

p53	B-GP
protein	O
and	O
MBP	B-GP
-	O
E6	B-GP
proteins	I-GP
were	O
blotted	O
using	O
p53	B-GP
(	O
pAB1801	O
)	O
and	O
anti	O
-	O
E6	B-GP
antibody	B-GP
(	O
AVR	O
813	O
).	O

(	O
D	O
)	O
Densitometric	O
analysis	O
of	O
p53	B-GP
protein	O
expressed	O
as	O
fold	O
change	O
over	O
p53	B-GP
control	O
for	O
wild	O
-	O
type	O
E6	B-GP
and	O
R131A	O
in	O
response	O
to	O
increasing	O
CAF	O
-	O
26	O
.	O

All	O
data	O
are	O
expressed	O
as	O
S	O
.	O
E	O
.	O
M	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

Equilibration	O
of	O
R55A	O
and	O
R102A	O
proteins	O
with	O
CAF	O
-	O
25	O
or	O
CAF	O
-	O
26	O
resulted	O
in	O
a	O
ΔTm	O
saturation	O
curve	O
similar	O
to	O
wild	O
-	O
type	O
E6	B-GP
(	O
S2	O
and	O
S3	O
Figs	O
).	O

Mutant	O
proteins	O
R10A	O
and	O
L50G	O
displayed	O
slightly	O
higher	O
ΔTm	O
shifts	O
with	O
CAF	O
-	O
25	O
compared	O
to	O
wild	O
-	O
type	O
,	O
but	O
lacked	O
statistical	O
significance	O
(	O
S2	O
Fig	O
).	O

CAF	O
-	O
26	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
ΔTm	O
of	O
R10A	O
protein	O
at	O
50	O
μM	O
compared	O
to	O
wild	O
-	O
type	O
,	O
while	O
L50G	O
exhibited	O
a	O
saturation	O
curve	O
similar	O
to	O
wild	O
-	O
type	O
(	O
S3	O
Fig	O
).	O

CAF	O
-	O
25	O
shifted	O
the	O
binding	O
curve	O
of	O
MBP	B-GP
-	O
E6	B-GP
R131A	O
to	O
a	O
higher	O
apparent	O
Kd	O
(	O
R131A	O
vs	O
.	O
wild	O
-	O
type	O
:	O
13	O
.	O
5	O
±	O
2	O
.	O
7	O
vs	O
.	O
7	O
.	O
3	O
±	O
2	O
.	O
7	O
μM	O
),	O
a	O
result	O
of	O
a	O
higher	O
ΔTm	O
shift	O
at	O
50	O
μM	O
(	O
Fig	O
7A	O
),	O
while	O
CAF	O
-	O
26	O
led	O
to	O
higher	O
ΔTm	O
changes	O
of	O
R131A	O
even	O
at	O
low	O
concentrations	O
(	O
Fig	O
7B	O
).	O

Unexpectedly	O
,	O
the	O
thermal	O
denaturation	O
profiles	O
of	O
the	O
E6	B-GP
mutants	O
with	O
CAF	O
-	O
27	O
resembled	O
wild	O
-	O
type	O
(	O
S4	O
Fig	O
).	O

R55A	O
showed	O
a	O
decreased	O
ΔTm	O
shift	O
at	O
the	O
highest	O
concentration	O
of	O
50	O
μM	O
at	O
which	O
saturation	O
seemed	O
to	O
occur	O
.	O

It	O
is	O
possible	O
that	O
the	O
elongated	O
structure	O
of	O
CAF	O
-	O
27	O
is	O
flexible	O
and	O
adjusts	O
to	O
the	O
changes	O
in	O
the	O
mutant	O
E6	B-GP
protein	I-GP
structure	O
.	O

However	O
,	O
due	O
to	O
the	O
absence	O
of	O
effects	O
across	O
all	O
E6	B-GP
mutant	O
proteins	O
,	O
it	O
seems	O
more	O
likely	O
that	O
this	O
compound	O
has	O
a	O
lower	O
binding	O
dependence	O
for	O
the	O
arginine	O
residues	O
targeted	O
in	O
this	O
study	O
.	O

The	O
unanticipated	O
flexibility	O
of	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
helix	O
-	O
groove	O
interaction	O
sites	O
could	O
account	O
for	O
the	O
minimal	O
impact	O
on	O
thermal	O
stabilities	O
of	O
the	O
arginine	O
point	O
mutants	O
in	O
combination	O
with	O
ligands	O
.	O

The	O
observed	O
increased	O
thermal	O
stabilization	O
of	O
R131A	O
with	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
26	O
suggests	O
that	O
mutation	O
to	O
alanine	O
provides	O
improved	O
steric	O
access	O
to	O
the	O
pocket	O
,	O
leading	O
to	O
increased	O
interactions	O
with	O
R10	O
and	O
opposed	O
R129	O
in	O
addition	O
to	O
stabilization	O
by	O
K11	O
as	O
seen	O
in	O
wild	O
-	O
type	O
.	O

Precedence	O
for	O
an	O
apparent	O
increased	O
binding	O
has	O
been	O
reported	O
for	O
the	O
E6	B-GP
R129A	O
mutation	O
using	O
a	O
luciferase	B-GP
-	O
based	O
interaction	O
assay	O
with	O
a	O
novel	O
peptide	O
,	O
while	O
R129E	O
reduced	O
the	O
effect	O
[	O
18	O
].	O

To	O
further	O
substantiate	O
the	O
finding	O
with	O
the	O
R131A	O
protein	O
,	O
the	O
p53	B-GP
in	O
vitro	O
degradation	O
assay	O
was	O
conducted	O
in	O
the	O
presence	O
of	O
increasing	O
concentrations	O
of	O
CAF	O
-	O
26	O
.	O

As	O
shown	O
in	O
Fig	O
7C	O
and	O
7D	O
,	O
R131A	O
induced	O
p53	B-GP
reduction	O
was	O
inhibited	O
by	O
~	O
5	O
times	O
the	O
IC50	O
of	O
CAF	O
-	O
26	O
relative	O
to	O
wild	O
-	O
type	O
,	O
consistent	O
with	O
the	O
TSA	O
binding	O
data	O
.	O

The	O
benzoic	O
acid	O
-	O
based	O
flavonoid	O
analog	O
CAF	O
-	O
40	O
stabilized	O
wild	O
-	O
type	O
E6	B-GP
as	O
well	O
as	O
the	O
R10A	O
,	O
L50G	O
and	O
R131A	O
mutant	O
proteins	O
(	O
S5A	O
,	O
S5B	O
and	O
S5E	O
Fig	O
),	O
whereas	O
binding	O
to	O
R102A	O
showed	O
a	O
higher	O
calculated	O
Kd	O
(	O
S5D	O
Fig	O
and	O
S2	O
Table	O
).	O

A	O
similar	O
effect	O
was	O
observed	O
with	O
the	O
R55A	O
mutant	O
,	O
but	O
the	O
data	O
were	O
not	O
statistically	O
significant	O
(	O
S5C	O
Fig	O
and	O
S2	O
Table	O
).	O

Since	O
the	O
R102A	O
mutant	O
has	O
very	O
low	O
p53	B-GP
in	O
vitro	O
degradation	O
activity	O
,	O
inhibitory	O
effects	O
of	O
CAF	O
-	O
40	O
were	O
not	O
evaluated	O
.	O

These	O
experimental	O
results	O
were	O
evaluated	O
in	O
the	O
context	O
of	O
MD	O
simulations	O
to	O
provide	O
an	O
additional	O
basis	O
for	O
understanding	O
the	O
relevant	O
residues	O
involved	O
in	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP
-	O
ligand	O
interactions	O
.	O

As	O
before	O
,	O
the	O
simulations	O
were	O
executed	O
with	O
the	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
E6	B-GP
antagonists	O
.	O

For	O
E6	B-GP
,	O
R10A	O
,	O
R55A	O
and	O
R131A	O
proteins	O
,	O
R102	O
maintained	O
contact	O
with	O
the	O
CAF	O
-	O
25	O
ligand	O
throughout	O
the	O
majority	O
of	O
the	O
simulation	O
time	O
frame	O
(	O
S6	O
Fig	O
).	O

In	O
the	O
case	O
where	O
R102	O
was	O
mutated	O
to	O
alanine	O
,	O
the	O
amount	O
of	O
contact	O
between	O
R131	O
and	O
the	O
ligand	O
increased	O
.	O

Furthermore	O
,	O
the	O
apparent	O
interaction	O
of	O
CAF	O
-	O
25	O
with	O
C51	O
in	O
E6	B-GP
was	O
found	O
to	O
play	O
a	O
major	O
role	O
in	O
nearly	O
every	O
simulation	O
frame	O
of	O
R10A	O
,	O
R55A	O
and	O
R131A	O
,	O
but	O
was	O
limited	O
in	O
mutants	O
L50G	O
and	O
R102A	O
.	O

In	O
regards	O
to	O
L50G	O
,	O
other	O
hydrophobic	O
residues	O
in	O
the	O
E6	B-GP
pocket	O
appear	O
to	O
resume	O
this	O
interaction	O
,	O
and	O
the	O
ligand	O
is	O
stabilized	O
by	O
R10	O
instead	O
of	O
adjunct	O
K11	O
,	O
and	O
R131	O
instead	O
of	O
its	O
opposing	O
residue	O
R102	O
on	O
the	O
outer	O
surface	O
of	O
the	O
pocket	O
.	O

The	O
interaction	O
of	O
R102A	O
with	O
CAF	O
-	O
25	O
may	O
induce	O
an	O
alternative	O
ligand	O
position	O
that	O
is	O
stabilized	O
by	O
residues	O
further	O
outside	O
of	O
the	O
pocket	O
,	O
in	O
particular	O
by	O
interactions	O
with	O
I128	O
,	O
R129	O
,	O
G130	O
and	O
substantially	O
by	O
R131	O
(	O
S6D	O
Fig	O
).	O

When	O
the	O
experimental	O
results	O
were	O
compared	O
with	O
the	O
MD	O
simulation	O
data	O
for	O
CAF	O
-	O
40	O
with	O
mutant	O
E6	B-GP
proteins	I-GP
(	O
S7	O
Fig	O
),	O
it	O
became	O
evident	O
that	O
interaction	O
between	O
the	O
carboxylate	O
group	O
and	O
R10	O
was	O
minimal	O
,	O
which	O
is	O
consistent	O
with	O
the	O
TSA	O
results	O
(	O
S7A	O
Fig	O
).	O

Further	O
,	O
R55	O
was	O
not	O
observed	O
to	O
interact	O
with	O
CAF	O
-	O
40	O
in	O
E6	B-GP
MD	O
simulations	O
,	O
whereas	O
its	O
importance	O
increased	O
significantly	O
in	O
the	O
R10A	O
,	O
L50G	O
and	O
R131A	O
mutant	O
proteins	O
(	O
S7B	O
and	O
S7C	O
Fig	O
).	O

E6	B-GP
MD	O
simulations	O
also	O
predict	O
a	O
negligible	O
direct	O
interaction	O
between	O
CAF	O
-	O
40	O
and	O
R102	O
,	O
whereas	O
binding	O
data	O
suggests	O
R102	O
is	O
important	O
to	O
CAF	O
-	O
40	O
binding	O
(	O
R102A	O
mutant	O
,	O
S2	O
Table	O
).	O

This	O
discrepancy	O
can	O
be	O
explained	O
by	O
thorough	O
analysis	O
of	O
the	O
R102A	O
MD	O
results	O
–	O
the	O
R102A	O
mutation	O
does	O
not	O
directly	O
impact	O
CAF	O
-	O
40	O
binding	O
(	O
S7D	O
Fig	O
).	O

However	O
,	O
it	O
leads	O
to	O
a	O
shift	O
in	O
the	O
position	O
of	O
R131	O
such	O
that	O
it	O
is	O
no	O
longer	O
able	O
to	O
participate	O
in	O
direct	O
H	O
-	O
bonding	O
with	O
the	O
carboxylate	O
moiety	O
,	O
but	O
does	O
so	O
through	O
a	O
water	O
molecule	O
(	O
S7E	O
Fig	O
).	O

The	O
entire	O
ligand	O
shifts	O
down	O
,	O
picking	O
up	O
a	O
new	O
π	O
-	O
cation	O
interaction	O
with	O
R10	O
,	O
but	O
this	O
is	O
insufficient	O
to	O
make	O
up	O
for	O
the	O
loss	O
of	O
direct	O
R131	O
H	O
-	O
bonding	O
(	O
S7F	O
Fig	O
).	O

This	O
analysis	O
is	O
also	O
supported	O
by	O
the	O
distances	O
between	O
the	O
R102	O
side	O
chain	O
and	O
the	O
carboxylate	O
group	O
in	O
CAF	O
-	O
40	O
(	O
3	O
.	O
4Å	O
and	O
4	O
.	O
5Å	O
,	O
E6	B-GP
MD	O
),	O
which	O
are	O
outside	O
of	O
the	O
typical	O
H	O
-	O
bond	O
length	O
(≈	O
3	O
Å	O
).	O

In	O
the	O
case	O
of	O
the	O
R131A	O
mutant	O
,	O
the	O
loss	O
of	O
H	O
-	O
bonding	O
and	O
π	O
-	O
cation	O
contacts	O
is	O
so	O
significant	O
that	O
CAF	O
-	O
40	O
rotates	O
180	O
°	O
to	O
facilitate	O
a	O
highly	O
-	O
efficient	O
interaction	O
with	O
R102	O
.	O

Interestingly	O
,	O
in	O
the	O
MD	O
simulations	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
protein	I-GP
,	O
there	O
was	O
a	O
CAF	O
-	O
40	O
interaction	O
with	O
L50	O
during	O
the	O
entire	O
simulation	O
frame	O
.	O

However	O
,	O
in	O
the	O
L50G	O
protein	O
,	O
CAF	O
-	O
40	O
was	O
increasingly	O
stabilized	O
by	O
adjacent	O
hydrophobic	O
residues	O
in	O
the	O
pocket	O
,	O
as	O
well	O
as	O
by	O
R55	O
,	O
R102	O
,	O
R129	O
,	O
R131	O
on	O
the	O
outer	O
surface	O
.	O

These	O
compensatory	O
features	O
may	O
account	O
for	O
the	O
observed	O
similar	O
thermal	O
profiles	O
of	O
L50G	O
and	O
wild	O
-	O
type	O
.	O

The	O
stabilization	O
of	O
L50G	O
by	O
these	O
E6	B-GP
inhibitors	O
is	O
an	O
observation	O
as	O
L50G	O
fails	O
to	O
bind	O
E6AP	B-GP
and	O
is	O
unable	O
to	O
initiate	O
p53	B-GP
degradation	O
.	O

Nonetheless	O
,	O
previous	O
research	O
showed	O
that	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
L50G	O
binds	O
p300	B-GP
and	O
inhibits	O
transcriptional	O
down	O
regulation	O
of	O
p53	B-GP
[	O
31	O
],	O
binds	O
to	O
the	O
hTERT	B-GP
promoter	O
[	O
30	O
],	O
interacts	O
with	O
ING4	B-GP
and	O
inhibits	O
p53	B-GP
acetylation	O
similar	O
to	O
wild	O
-	O
type	O
E6	B-GP
protein	I-GP
[	O
41	O
,	O
42	O
].	O

Together	O
these	O
data	O
indicate	O
that	O
the	O
tested	O
tetrazole	O
-	O
based	O
compounds	O
have	O
greater	O
flexibility	O
than	O
CAF	O
-	O
40	O
in	O
binding	O
to	O
the	O
E6	B-GP
protein	I-GP
.	O

Structure	O
-	O
guided	O
approaches	O
to	O
design	O
small	O
molecule	O
antagonists	O
for	O
helix	O
-	O
groove	O
protein	O
-	O
protein	O
interactions	O
have	O
been	O
successfully	O
deployed	O
in	O
a	O
few	O
cases	O
such	O
as	O
MDM2	B-GP
-	O
p53	B-GP
[	O
43	O
].	O

A	O
structure	O
-	O
based	O
design	O
for	O
discovery	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
antagonists	O
will	O
require	O
consideration	O
of	O
the	O
unique	O
features	O
of	O
the	O
hydrophobic	O
groove	O
.	O

Since	O
the	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
target	O
specificity	O
allows	O
degeneracy	O
,	O
the	O
challenge	O
of	O
understanding	O
what	O
mediates	O
the	O
primary	O
protein	O
-	O
protein	O
interactions	O
could	O
partially	O
be	O
explained	O
by	O
the	O
attributes	O
of	O
compensatory	O
roles	O
of	O
charged	O
side	O
chain	O
residues	O
revealed	O
in	O
these	O
studies	O
.	O

More	O
importantly	O
,	O
the	O
role	O
that	O
these	O
residues	O
play	O
in	O
forming	O
the	O
shape	O
of	O
the	O
helix	O
groove	O
is	O
now	O
observed	O
to	O
be	O
more	O
critical	O
.	O

In	O
Fig	O
8A	O
are	O
highlighted	O
examples	O
of	O
how	O
the	O
rim	O
arginines	O
relate	O
to	O
the	O
non	O
-	O
hydrophobic	O
volume	O
that	O
defines	O
the	O
E6	B-GP
protein	I-GP
,	O
when	O
occupied	O
with	O
an	O
alpha	O
helical	O
binding	O
partner	O
.	O
Fig	O
8B	O
and	O
8C	O
shows	O
the	O
extensive	O
network	O
of	O
charged	O
and	O
hydrogen	O
binding	O
interactions	O
that	O
relate	O
to	O
trans	O
-	O
groove	O
interactions	O
and	O
maintain	O
helical	O
partner	O
protein	O
contacts	O
.	O

The	O
two	O
examples	O
of	O
R131	O
and	O
R102	O
are	O
particularly	O
noteworthy	O
,	O
given	O
how	O
the	O
non	O
-	O
bonding	O
interactions	O
form	O
the	O
bottom	O
of	O
the	O
groove	O
and	O
likely	O
stabilize	O
the	O
alpha	O
helical	O
features	O
of	O
the	O
peptide	O
.	O

The	O
rim	O
arginines	O
R10	O
,	O
R55	O
,	O
R102	O
,	O
R129	O
,	O
and	O
R131	O
play	O
a	O
major	O
role	O
in	O
the	O
shape	O
of	O
the	O
E6	B-GP
helical	O
binding	O
groove	O
,	O
as	O
well	O
as	O
in	O
molecular	O
recognition	O
of	O
the	O
binding	O
partners	O
.	O

(	O
A	O
)	O
The	O
arginine	O
residues	O
(	O
yellow	O
-	O
gold	O
color	O
)	O
form	O
multiple	O
polar	O
contacts	O
(	O
blue	O
dotted	O
lines	O
)	O
with	O
E6AP	B-GP
(	O
green	O
backbone	O
),	O
which	O
are	O
proposed	O
to	O
contribute	O
to	O
its	O
binding	O
affinity	O
and	O
alpha	O
-	O
helical	O
shape	O
(	O
B	O
,	O
C	O
).	O

Concurrently	O
,	O
the	O
rim	O
arginines	O
also	O
form	O
important	O
intra	O
-	O
molecular	O
polar	O
contacts	O
(	O
blue	O
doted	O
lines	O
;	O
all	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
residues	O
involved	O
in	O
polar	O
contacts	O
with	O
the	O
rim	O
arginines	O
are	O
colored	O
red	O
),	O
which	O
are	O
believed	O
to	O
shape	O
the	O
floor	O
and	O
sides	O
of	O
the	O
groove	O
.	O

R102	O
is	O
important	O
for	O
groove	O
floor	O
formation	O
(	O
B	O
),	O
while	O
R131	O
plays	O
a	O
role	O
in	O
forming	O
the	O
right	O
side	O
of	O
the	O
binding	O
pocket	O
(	O
C	O
).	O

These	O
data	O
highlight	O
the	O
benefit	O
of	O
combined	O
experimental	O
and	O
molecular	O
dynamics	O
modeling	O
approaches	O
to	O
gain	O
perspective	O
into	O
the	O
types	O
of	O
molecular	O
interactions	O
that	O
contribute	O
to	O
binding	O
in	O
the	O
hydrophobic	O
groove	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
.	O

While	O
the	O
original	O
concept	O
of	O
developing	O
a	O
pharmacophore	O
based	O
upon	O
a	O
hydrophobic	O
patch	O
in	O
the	O
E6	B-GP
helix	O
-	O
binding	O
groove	O
provided	O
the	O
first	O
class	O
of	O
inhibitors	O
,	O
the	O
nature	O
of	O
the	O
ligand	O
interactions	O
are	O
different	O
than	O
expected	O
[	O
25	O
,	O
44	O
].	O

From	O
exploration	O
of	O
the	O
benzopyranone	O
scaffold	O
,	O
there	O
are	O
important	O
features	O
of	O
E6	B-GP
that	O
have	O
been	O
revealed	O
,	O
which	O
can	O
impact	O
future	O
design	O
strategies	O
for	O
E6	B-GP
inhibitory	O
compounds	O
.	O

The	O
results	O
here	O
indicate	O
that	O
considerations	O
of	O
both	O
the	O
flexibility	O
as	O
well	O
as	O
the	O
electrostatic	O
features	O
of	O
the	O
helix	O
binding	O
groove	O
will	O
be	O
useful	O
.	O

These	O
observations	O
are	O
interesting	O
in	O
light	O
of	O
recent	O
roles	O
of	O
electrostatic	O
interactions	O
in	O
the	O
rim	O
of	O
the	O
MDM2	B-GP
alpha	O
-	O
helix	O
binding	O
groove	O
used	O
to	O
design	O
more	O
potent	O
and	O
selective	O
inhibitors	O
[	O
45	O
].	O

Unlike	O
MDM2	B-GP
,	O
a	O
hotspot	O
in	O
the	O
hydrophobic	O
floor	O
of	O
the	O
E6	B-GP
groove	O
has	O
not	O
been	O
easily	O
identifiable	O
for	O
specific	O
inhibitor	O
design	O
[	O
46	O
].	O

More	O
likely	O
,	O
the	O
hydrophobic	O
groove	O
contacts	O
accommodate	O
more	O
degeneracy	O
in	O
molecular	O
recognition	O
of	O
target	O
proteins	O
given	O
the	O
multiple	O
binding	O
partners	O
and	O
diverse	O
biological	O
activities	O
of	O
E6	B-GP
.	O

Methods	O

Cloning	O
and	O
site	O
-	O
directed	O
mutagenesis	O

MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
cloned	O
in	O
pETM	O
-	O
41	O
was	O
a	O
kind	O
gift	O
of	O
G	O
.	O

Travé	O
.	O

Mutations	O
of	O
MBP	B-GP
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
as	O
well	O
as	O
pLXSN	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
were	O
performed	O
using	O
Finnzymes	O
'	O
Phire	O
®	O
Hot	O
Start	O
DNA	B-GP
Polymerase	I-GP
(	O
Thermo	O
Scientific	O
).	O

The	O
MBP	B-GP
control	O
vector	O
was	O
generated	O
by	O
inverse	O
PCR	O
using	O
5	O
'-	O
end	O
phosphorylated	O
Primers	O
and	O
Phire	O
Hot	O
Start	O
polymerase	B-GP
(	O
S1	O
Table	O
).	O

Primers	O
used	O
for	O
the	O
site	O
-	O
directed	O
mutagenesis	O
are	O
summarized	O
in	O
S1	O
Table	O
.	O

Protein	O
expression	O
and	O
purification	O

Protein	O
purification	O
of	O
MBP	B-GP
,	O
MBP	B-GP
-	O
HPV16	B-OG
E6	B-GP
and	O
its	O
mutants	O
was	O
performed	O
as	O
described	O
[	O
25	O
]	O
with	O
the	O
following	O
variations	O
.	O

In	O
brief	O
,	O
plasmids	O
were	O
transformed	O
in	O
BL21	B-OG
(	I-OG
DE3	I-OG
)	I-OG
E	I-OG
.	I-OG
coli	I-OG
and	O
clones	O
were	O
grown	O
in	O
10	O
ml	O
of	O
TurboBrothTM	O
(	O
AthenaES	O
)	O
supplemented	O
with	O
0	O
.	O
04	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	O
.	O

Protein	O
stocks	O
were	O
prepared	O
as	O
2	O
ml	O
frozen	O
E	B-OG
.	I-OG
coli	I-OG
aliquots	O
(	O
20	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
).	O

For	O
protein	O
production	O
2	O
ml	O
of	O
the	O
bacterial	O
stock	O
was	O
inoculated	O
with	O
200	O
ml	O
Turbo	O
-	O
broth	O
supplemented	O
with	O
0	O
.	O
05	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	O
,	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
lactose	O
,	O
0	O
.	O
6	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
and	O
incubated	O
at	O
20	O
°	O
C	O
,	O
200	O
rpm	O
for	O
30	O
h	O
.	O

Cells	O
were	O
collected	O
at	O
6000xg	O
,	O
15	O
min	O
,	O
4	O
°	O
C	O
.	O

The	O
pellet	O
was	O
resuspended	O
in	O
400	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
6	O
.	O
8	O
,	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
NP	O
-	O
40	O
,	O
2	O
.	O
5	O
mM	O
DTT	O
and	O
1x	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
EDTA	O
-	O
free	O
;	O
Sigma	O
-	O
Aldrich	O
).	O

The	O
cells	O
were	O
sonicated	O
and	O
suspension	O
was	O
cleared	O
at	O
15	O
,	O
000x	O
g	O
,	O
4	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
supernatant	O
was	O
incubated	O
with	O
amylose	O
beads	O
(	O
NE	O
Biolabs	O
)	O
rotating	O
at	O
4	O
°	O
C	O
for	O
2h	O
.	O

The	O
beads	O
were	O
washed	O
once	O
with	O
lysis	O
buffer	O
in	O
10	O
times	O
the	O
bed	O
volume	O
.	O

Subsequent	O
washes	O
were	O
performed	O
with	O
lysis	O
buffer	O
without	O
NP	O
-	O
40	O
.	O

Proteins	O
on	O
beads	O
were	O
collected	O
in	O
storage	O
buffer	O
(	O
400	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
6	O
.	O
8	O
,	O
2	O
mM	O
DTT	O
,	O
1x	O
protease	B-GP
inhibitor	O
)	O
or	O
eluted	O
with	O
Maltose	O
at	O
a	O
final	O
concentration	O
of	O
10	O
mM	O
for	O
1h	O
rotating	O
at	O
4	O
°	O
C	O
.	O

Eluted	O
proteins	O
were	O
cleared	O
by	O
centrifugation	O
at	O
3000xg	O
,	O
4	O
°	O
C	O
,	O
5	O
min	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
Bradford	O
assay	O
and	O
were	O
diluted	O
to	O
1	O
μg	O
/	O
μl	O
with	O
storage	O
buffer	O
containing	O
10	O
mM	O
maltose	O
.	O

E6AP	B-GP
-	O
BAP	B-GP
(	O
pET	O
-	O
24a	O
)	O
was	O
transformed	O
into	O
BL21	B-OG
(	I-OG
DE3	I-OG
)	I-OG
E	I-OG
.	I-OG
coli	I-OG
.	O

Clones	O
were	O
picked	O
and	O
inoculated	O
in	O
10	O
ml	O
of	O
TurboBroth	O
supplemented	O
with	O
0	O
.	O
04	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	O
.	O

Protein	O
stocks	O
were	O
prepared	O
as	O
1	O
ml	O
frozen	O
E	B-OG
.	I-OG
coli	I-OG
aliquots	O
(	O
20	O
%(	O
v	O
/	O
v	O
)	O
glycerol	O
).	O

For	O
protein	O
production	O
,	O
2ml	O
of	O
the	O
bacterial	O
stock	O
was	O
inoculated	O
with	O
300	O
ml	O
Turbo	O
-	O
broth	O
supplemented	O
with	O
0	O
.	O
05	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	O
,	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
lactose	O
,	O
0	O
.	O
6	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
and	O
incubated	O
at	O
37	O
°	O
C	O
,	O
200	O
rpm	O
for	O
4h	O
followed	O
by	O
24h	O
at	O
20	O
°	O
C	O
,	O
200	O
rpm	O
.	O

Cells	O
were	O
collected	O
as	O
described	O
earlier	O
and	O
resuspended	O
in	O
100	O
mM	O
NaCl	O
,	O
100	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
and	O
1x	O
protease	B-GP
inhibitor	O
followed	O
by	O
sonication	O
as	O
described	O
above	O
.	O

Supernatant	O
was	O
incubated	O
with	O
200	O
μl	O
anti	O
-	O
flag	O
resin	O
(	O
50	O
%	O
slurry	O
,	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
4h	O
,	O
rotating	O
,	O
4	O
°	O
C	O
.	O

This	O
mixture	O
was	O
transferred	O
to	O
an	O
EconoColumn	O
and	O
washed	O
with	O
10	O
bed	O
volumes	O
of	O
100	O
mM	O
NaCl	O
,	O
100	O
mM	O
Tris	O
-	O
HCl	O
,	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
NP	O
-	O
40	O
and	O
1x	O
protease	B-GP
inhibitor	O
.	O

E6AP	B-GP
-	O
BAP	B-GP
was	O
eluted	O
with	O
5	O
successive	O
elutions	O
of	O
ice	O
-	O
cold	O
0	O
.	O
1	O
M	O
glycine	O
pH	O
2	O
.	O
0	O
into	O
250	O
μl	O
of	O
Neutralization	O
buffer	O
(	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
,	O
200	O
NaCl	O
,	O
200	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
2x	O
protease	B-GP
inhibitor	O
cocktail	O
).	O

All	O
bacterial	O
expressed	O
proteins	O
were	O
stored	O
at	O
4	O
°	O
C	O
and	O
used	O
within	O
5	O
days	O
after	O
purification	O
.	O

Human	B-OG
p53	B-GP
proteins	O
were	O
expressed	O
in	O
High	O
5	O
cells	O
using	O
human	B-OG
p53	B-GP
baculovirus	B-OG
that	O
was	O
a	O
kind	O
gift	O
from	O
Carol	O
Prives	O
.	O

Cells	O
were	O
rinsed	O
with	O
PBS	O
and	O
incubated	O
with	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
6	O
.	O
8	O
,	O
400	O
mM	O
NaCl	O
,	O
0	O
.	O
4	O
%	O
(	O
v	O
/	O
v	O
)	O
NP	O
-	O
40	O
,	O
2	O
mM	O
DTT	O
)	O
and	O
1x	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
EDTA	O
-	O
free	O
).	O

Lysate	O
was	O
cleared	O
by	O
centrifugation	O
at	O
20	O
,	O
000xg	O
and	O
diluted	O
in	O
lysis	O
buffer	O
1	O
:	O
200	O
.	O

P53	B-GP
protein	O
levels	O
were	O
evaluated	O
by	O
immunoblotting	O
using	O
D0	O
-	O
1	O
and	O
PAB1801	O
antibody	B-GP
.	O

p53	B-GP
degradation	O
assays	O

In	O
vitro	O
p53	B-GP
degradation	O
assays	O
were	O
performed	O
in	O
a	O
30	O
μL	O
reaction	O
in	O
assay	O
buffer	O
(	O
25	O
mM	O
Tris	O
HCl	O
pH	O
7	O
.	O
5	O
,	O
100	O
mM	O
NaCl	O
,	O
2	O
mM	O
DTT	O
,	O
2	O
.	O
5	O
mM	O
ATP	O
)	O
containing	O
1	O
μl	O
rabbit	B-OG
reticulocyte	O
lysate	O
(	O
RRL	O
),	O
p53	B-GP
,	O
E6	B-GP
proteins	I-GP
or	O
E6	B-GP
buffer	O
.	O

Reactions	O
were	O
incubated	O
for	O
2h	O
at	O
25	O
°	O
C	O
unless	O
otherwise	O
stated	O
and	O
were	O
stopped	O
by	O
incubation	O
at	O
75	O
°	O
C	O
.	O

For	O
inhibition	O
studies	O
,	O
E6	B-GP
proteins	I-GP
were	O
diluted	O
to	O
0	O
.	O
1μM	O
and	O
equilibrated	O
with	O
assay	O
buffer	O
containing	O
0	O
.	O
35	O
%	O
(	O
v	O
/	O
v	O
)	O
DMSO	O
,	O
or	O
compounds	O
at	O
different	O
concentrations	O
for	O
1h	O
,	O
followed	O
by	O
the	O
addition	O
of	O
p53	B-GP
and	O
RRL	O
and	O
incubation	O
at	O
25	O
°	O
C	O
for	O
2h	O
.	O

Proteins	O
were	O
separated	O
on	O
10	O
%	O
SDS	O
page	O
,	O
transferred	O
onto	O
PVDF	O
membrane	O
and	O
blotted	O
for	O
p53	B-GP
using	O
Pab1801	O
antibody	B-GP
.	O

Blots	O
were	O
stripped	O
and	O
re	O
-	O
probed	O
with	O
anti	O
-	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
antibody	B-GP
(	O
ArborVita	O
Inc	O
.).	O

All	O
p53	B-GP
degradation	O
experiments	O
were	O
repeated	O
at	O
least	O
three	O
independent	O
times	O
.	O

The	O
p53	B-GP
in	O
vivo	O
degradation	O
assay	O
was	O
performed	O
as	O
described	O
with	O
the	O
following	O
modifications	O
[	O
40	O
].	O

C33A	O
cells	O
were	O
transfected	O
with	O
pRluc	O
-	O
p53	B-GP
(	O
215	O
ng	O
),	O
pCI	O
-	O
Fluc	O
(	O
135	O
ng	O
),	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
expression	O
vectors	O
(	O
0	O
,	O
18	O
.	O
5	O
,	O
54	O
,	O
270	O
,	O
540	O
,	O
1080	O
ng	O
)	O
and	O
carrier	O
DNA	O
(	O
up	O
to	O
1080	O
ng	O
,	O
pBabePuro	O
)	O
using	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
with	O
OptiMem	O
media	O
.	O

24h	O
later	O
,	O
cells	O
were	O
lysed	O
using	O
the	O
Dual	O
Glo	O
Luciferase	B-GP
Assay	O
System	O
(	O
Promega	O
)	O
and	O
each	O
6	O
-	O
well	O
sample	O
was	O
aliquoted	O
into	O
four	O
replicates	O
into	O
a	O
96	O
well	O
plate	O
.	O

Renilla	B-OG
luciferase	B-GP
levels	O
were	O
normalized	O
to	O
firefly	B-OG
luciferase	B-GP
.	O

The	O
averages	O
of	O
the	O
three	O
independent	O
experiments	O
were	O
plotted	O
using	O
GraphPad	O
Prism	O
.	O

MBP	B-GP
-	O
E6	B-GP
and	O
E6AP	B-GP
binding	O
assay	O

The	O
MBP	B-GP
-	O
E6	B-GP
/	O
E6AP	B-GP
binding	O
assay	O
was	O
performed	O
as	O
described	O
[	O
25	O
]	O
with	O
the	O
following	O
modifications	O
.	O

Filter	O
plates	O
(	O
0	O
.	O
45	O
μm	O
,	O
Millipore	O
,	O
MSHVN4B	O
)	O
were	O
blocked	O
with	O
binding	O
buffer	O
(	O
400	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
6	O
.	O
8	O
,	O
0	O
.	O
1	O
%	O
milk	O
)	O
for	O
1h	O
and	O
solution	O
was	O
removed	O
prior	O
to	O
addition	O
of	O
MPB	O
-	O
E6	B-GP
bound	O
amylose	O
beads	O
at	O
indicated	O
concentrations	O
or	O
at	O
0	O
.	O
67	O
μM	O
in	O
50	O
μl	O
binding	O
buffer	O
with	O
2	O
mM	O
DTT	O
.	O

For	O
background	O
subtraction	O
,	O
an	O
amylose	O
bead	O
control	O
was	O
included	O
.	O

MBP	B-GP
bound	O
proteins	O
were	O
blocked	O
in	O
binding	O
buffer	O
at	O
4	O
°	O
C	O
for	O
1h	O
.	O

Compounds	O
and	O
DMSO	O
were	O
added	O
in	O
2	O
μl	O
per	O
well	O
followed	O
by	O
rotating	O
equilibration	O
for	O
1h	O
at	O
room	O
temperature	O
.	O

Plates	O
were	O
vacuum	O
filtered	O
and	O
E6AP	B-GP
-	O
BAP	B-GP
(	O
aa	O
371	O
–	O
440	O
)	O
fusion	O
protein	O
was	O
added	O
at	O
50	O
nM	O
in	O
50	O
μl	O
of	O
binding	O
buffer	O
with	O
1	O
mM	O
DTT	O
.	O

Proteins	O
were	O
incubated	O
for	O
1	O
-	O
3h	O
at	O
room	O
temperature	O
.	O

Plates	O
were	O
filtered	O
and	O
washed	O
twice	O
with	O
wash	O
buffer	O
(	O
400	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
6	O
.	O
8	O
,	O
0	O
.	O
1	O
%	O
milk	O
)	O
supplemented	O
with	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
NP40	O
and	O
once	O
without	O
NP40	O
.	O

Immuno	O
-	O
Star	O
™	O
AP	O
reagent	O
(	O
Biorad	O
)	O
and	O
enhancer	O
were	O
prepared	O
at	O
a	O
ratio	O
of	O
1	O
:	O
100	O
and	O
60	O
μl	O
per	O
well	O
added	O
.	O

Reactions	O
developed	O
for	O
7	O
min	O
followed	O
by	O
filtering	O
the	O
plate	O
by	O
vacuum	O
.	O

Luminescence	O
was	O
measured	O
in	O
a	O
PHERAstar	O
FS	O
plate	O
reader	O
(	O
BMG	O
Labtech	O
).	O

Thermostability	O
assay	O
(	O
TSA	O
)	O

The	O
thermal	O
stability	O
assay	O
[	O
25	O
,	O
33	O
]	O
was	O
performed	O
with	O
the	O
following	O
modifications	O
.	O

All	O
proteins	O
were	O
diluted	O
to	O
a	O
final	O
concentration	O
of	O
1	O
μM	O
in	O
400	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
HCl	O
pH	O
6	O
.	O
8	O
and	O
incubated	O
with	O
compounds	O
at	O
the	O
indicated	O
concentrations	O
for	O
1hr	O
.	O

Compounds	O
were	O
tested	O
at	O
a	O
range	O
of	O
1	O
to	O
150	O
μM	O
.	O

All	O
compounds	O
were	O
pre	O
-	O
diluted	O
in	O
DMSO	O
resulting	O
a	O
final	O
concentration	O
of	O
1	O
.	O
8	O
%	O
(	O
v	O
/	O
v	O
)	O
DMSO	O
.	O

Sypro	O
Orange	O
(	O
Invitrogen	O
)	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
5X	O
.	O

Samples	O
were	O
analyzed	O
in	O
triplicate	O
(	O
25	O
μL	O
per	O
well	O
)	O
in	O
a	O
96	O
-	O
well	O
plate	O
using	O
a	O
Real	O
-	O
time	O
PCR	O
(	O
CFX96	O
Biorad	O
).	O

Fluorescence	O
was	O
measured	O
using	O
the	O
FRET	O
channel	O
of	O
CFX96	O
Real	O
-	O
Time	O
PCR	O
thermal	O
cycler	O
(	O
BioRad	O
)	O
over	O
a	O
temperature	O
range	O
of	O
25	O
°	O
C	O
to	O
95	O
°	O
C	O
.	O

Temperature	O
increments	O
were	O
set	O
to	O
0	O
.	O
5	O
°	O
C	O
for	O
30	O
sec	O
followed	O
by	O
plate	O
reading	O
.	O

In	O
the	O
same	O
fashion	O
,	O
all	O
compounds	O
were	O
evaluated	O
for	O
their	O
fluorescence	O
profile	O
in	O
the	O
absence	O
of	O
MBP	B-GP
-	O
E6	B-GP
.	O

Melt	O
curves	O
and	O
Tm	O
were	O
calculated	O
using	O
Biorad	O
CFX	O
manager	O
software	O
.	O

All	O
proteins	O
were	O
purified	O
three	O
independent	O
times	O
and	O
analysis	O
with	O
compounds	O
was	O
performed	O
at	O
least	O
two	O
times	O
in	O
duplicate	O
per	O
purification	O
run	O
.	O

The	O
average	O
of	O
each	O
individual	O
purification	O
run	O
was	O
determined	O
and	O
these	O
averages	O
of	O
the	O
purifications	O
were	O
plotted	O
using	O
Graph	O
-	O
Pad	O
Prism	O
(	O
v5	O
.	O
00	O
).	O

Results	O
were	O
analyzed	O
by	O
fitting	O
for	O
saturation	O
binding	O
curves	O
to	O
estimate	O
Kd	O
and	O
Bmax	O
values	O
from	O
the	O
best	O
fits	O
.	O

These	O
curves	O
were	O
analyzed	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
using	O
two	O
-	O
way	O
ANOVA	O
with	O
post	O
-	O
hoc	O
Bonferroni	O
analysis	O
for	O
comparison	O
to	O
wild	O
type	O
and	O
a	O
P	O
<	O
0	O
.	O
05	O
was	O
taken	O
as	O
statistically	O
significant	O
.	O

Virtual	O
docking	O
studies	O

Computational	O
studies	O
were	O
performed	O
using	O
the	O
Schrödinger	O
Maestro	O
software	O
package	O
.	O

The	O
ligands	O
were	O
uploaded	O
to	O
Maestro	O
and	O
ionized	O
(	O
along	O
with	O
desalting	O
and	O
tautomerization	O
)	O
using	O
Epik	O
,	O
in	O
order	O
to	O
generate	O
all	O
possible	O
states	O
within	O
a	O
pH	O
range	O
of	O
7	O
.	O
0	O
±	O
2	O
.	O
0	O
.	O

The	O
output	O
structures	O
from	O
Epik	O
were	O
then	O
minimized	O
using	O
the	O
OPLS	O
-	O
2005	O
force	O
field	O
.	O

Starting	O
from	O
a	O
crystal	O
structure	O
of	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
(	O
derived	O
from	O
the	O
original	O
crystal	O
structure	O
4GIZ	O
,	O
through	O
a	O
set	O
of	O
induced	O
-	O
fit	O
simulations	O
,	O
which	O
allowed	O
for	O
larger	O
ligands	O
to	O
be	O
accommodated	O
by	O
the	O
binding	O
groove	O
),	O
five	O
mutants	O
were	O
generated	O
within	O
Maestro	O
through	O
the	O
Mutate	O
Residues	O
Script	O
(	O
L50G	O
,	O
R10A	O
,	O
R102A	O
,	O
R131A	O
,	O
R55A	O
)	O
[	O
47	O
,	O
48	O
].	O

Each	O
mutant	O
was	O
prepared	O
using	O
the	O
Protein	O
Preparation	O
Wizard	O
and	O
minimized	O
in	O
complex	O
with	O
the	O
CAF	O
-	O
40	O
ligand	O
to	O
an	O
RMSD	O
of	O
0	O
.	O
30Å	O
,	O
using	O
the	O
OPLS	O
-	O
2005	O
force	O
field	O
.	O

The	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
ligands	O
were	O
then	O
flexibly	O
docked	O
into	O
the	O
resulting	O
crystal	O
structure	O
via	O
the	O
induced	O
-	O
fit	O
algorithm	O
,	O
with	O
protein	O
flexibility	O
within	O
10Å	O
of	O
each	O
ligand	O
.	O

The	O
output	O
structures	O
of	O
the	O
Induced	O
Fit	O
docking	O
runs	O
were	O
further	O
subjected	O
to	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
.	O

Solvated	O
models	O
of	O
each	O
mutant	O
and	O
wild	O
-	O
type	O
E6	B-GP
structure	O
,	O
along	O
with	O
their	O
ligands	O
,	O
were	O
created	O
using	O
Desmond	O
.	O

Details	O
of	O
Molecular	O
Docking	O
and	O
Dynamics	O

E6	B-GP
-	O
ligand	O
complexes	O
were	O
solvated	O
with	O
the	O
TIP3P	O
water	O
model	O
in	O
the	O
presence	O
of	O
0	O
.	O
15	O
M	O
sodium	O
chloride	O
buffer	O
.	O

An	O
orthorhombic	O
water	O
box	O
was	O
generated	O
with	O
a	O
10	O
Å	O
buffer	O
region	O
,	O
all	O
overlapping	O
water	O
molecules	O
were	O
removed	O
,	O
and	O
the	O
system	O
was	O
neutralized	O
in	O
the	O
presence	O
of	O
sodium	O
cations	O
.	O

The	O
resulting	O
solvated	O
systems	O
were	O
then	O
minimized	O
with	O
the	O
OPLS	O
-	O
2005	O
force	O
field	O
.	O

Long	O
-	O
range	O
electrostatic	O
interactions	O
were	O
determined	O
using	O
a	O
smooth	O
particle	O
mesh	O
Ewald	O
method	O
,	O
with	O
a	O
grid	O
spacing	O
of	O
0	O
.	O
8	O
Å	O
.	O

For	O
non	O
-	O
bonded	O
van	O
der	O
Waals	O
interactions	O
,	O
a	O
cut	O
-	O
off	O
of	O
9	O
.	O
0	O
Å	O
was	O
set	O
.	O

All	O
simulations	O
were	O
performed	O
for	O
5	O
.	O
0	O
ns	O
using	O
the	O
Desmond	O
NPT	O
method	O
,	O
with	O
a	O
six	O
-	O
step	O
slow	O
relaxation	O
protocol	O
prior	O
to	O
the	O
molecular	O
dynamics	O
run	O
:	O
(	O
1	O
)	O
2000	O
step	O
limited	O
-	O
memory	O
Broyden	O
-	O
Fletcher	O
-	O
Goldfarb	O
-	O
Shanno	O
(	O
L	O
-	O
BFGS	O
)	O
minimization	O
,	O
with	O
a	O
loose	O
convergence	O
restraint	O
of	O
50	O
kcal	O
/	O
mol	O
/	O
Å	O
;	O
(	O
2	O
)	O
2000	O
step	O
L	O
-	O
BFGS	O
minimization	O
with	O
a	O
convergence	O
constraint	O
of	O
5	O
kcal	O
/	O
mol	O
/	O
Å	O
;	O
(	O
3	O
)	O
a	O
12	O
ps	O
Berendsen	O
NVT	O
simulation	O
at	O
a	O
temperature	O
of	O
10	O
K	O
,	O
with	O
restraints	O
on	O
solute	O
heavy	O
atoms	O
;	O
(	O
4	O
)	O
a	O
12	O
ps	O
Berendsen	O
NPT	O
ensemble	O
at	O
a	O
temperature	O
of	O
10	O
K	O
and	O
pressure	O
at	O
1	O
.	O
01325	O
bar	O
,	O
with	O
restraints	O
on	O
solute	O
heavy	O
atoms	O
;	O
(	O
5	O
)	O
a	O
24	O
ps	O
Berendsen	O
NPT	O
ensemble	O
at	O
a	O
temperature	O
of	O
300	O
K	O
and	O
a	O
pressure	O
at	O
1	O
.	O
01325	O
bar	O
with	O
restraints	O
on	O
solute	O
heavy	O
atoms	O
;	O
(	O
6	O
)	O
a	O
24	O
ps	O
Berendsen	O
NPT	O
ensemble	O
at	O
a	O
temperature	O
of	O
300	O
K	O
and	O
ds	O
<	O
a	O
pressure	O
at	O
1	O
.	O
01325	O
bar	O
,	O
with	O
restraints	O
on	O
residues	O
beyond	O
15	O
Å	O
of	O
the	O
restrained	O
ligand	O
[	O
49	O
].	O

The	O
5	O
.	O
0	O
ns	O
molecular	O
dynamic	O
simulation	O
run	O
was	O
performed	O
using	O
the	O
NPT	O
ensemble	O
.	O

The	O
temperature	O
of	O
the	O
simulation	O
was	O
kept	O
at	O
300	O
K	O
using	O
a	O
Nosé	O
-	O
Hoover	O
thermostat	O
.	O

Pressure	O
was	O
maintained	O
at	O
1	O
.	O
01325	O
bar	O
using	O
the	O
Martyna	O
-	O
Tobias	O
-	O
Klein	O
method	O
.	O

Energy	O
and	O
trajectory	O
data	O
were	O
recorded	O
at	O
every	O
1	O
.	O
2	O
ps	O
and	O
5	O
.	O
0	O
ps	O
,	O
respectively	O
.	O

After	O
completion	O
,	O
simulation	O
data	O
was	O
processed	O
for	O
each	O
structure	O
and	O
convergence	O
was	O
confirmed	O
by	O
measuring	O
the	O
RMSD	O
of	O
protein	O
side	O
chains	O
,	O
heavy	O
atoms	O
,	O
Cα	O
atoms	O
,	O
and	O
ligand	O
conformation	O
,	O
over	O
the	O
course	O
of	O
each	O
simulation	O
.	O

The	O
average	O
trajectories	O
of	O
the	O
final	O
50	O
frames	O
for	O
each	O
E6	B-GP
-	O
ligand	O
complex	O
were	O
generated	O
using	O
VMD	O
[	O
50	O
].	O

Simulation	O
interaction	O
details	O
were	O
obtained	O
using	O
Desmond	O
and	O
structure	O
images	O
were	O
created	O
using	O
Pymol	O
.	O

Finally	O
,	O
the	O
last	O
fifty	O
frames	O
of	O
each	O
MD	O
simulation	O
were	O
averaged	O
and	O
used	O
as	O
a	O
starting	O
structure	O
to	O
re	O
-	O
dock	O
CAF	O
-	O
25	O
and	O
CAF	O
-	O
40	O
with	O
the	O
Standard	O
Precision	O
(	O
SP	O
)	O
algorithm	O
.	O

This	O
method	O
does	O
not	O
involve	O
protein	O
flexibility	O
,	O
as	O
it	O
was	O
assumed	O
that	O
the	O
MD	O
ensemble	O
represents	O
the	O
lowest	O
energy	O
conformation	O
of	O
the	O
protein	O
.	O

The	O
docking	O
scores	O
from	O
the	O
SP	O
results	O
were	O
then	O
compared	O
to	O
the	O
reported	O
IC50	O
and	O
TSA	O
data	O
.	O

The	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
crystal	O
structure	O
used	O
for	O
initial	O
Induced	O
Fit	O
docking	O
was	O
previously	O
generated	O
starting	O
from	O
the	O
published	O
crystal	O
structure	O
(	O
PDB	O
ID	O
:	O
4GIZ	O
).	O

A	O
long	O
ligand	O
was	O
constructed	O
,	O
capable	O
of	O
spanning	O
the	O
distance	O
between	O
R55	O
and	O
W132	O
,	O
and	O
it	O
was	O
docked	O
flexibly	O
(	O
Induced	O
Fit	O
)	O
into	O
4GIZ	O
.	O

The	O
resulting	O
protein	O
structure	O
has	O
a	O
helix	O
groove	O
capable	O
of	O
accepting	O
larger	O
ligands	O
,	O
and	O
is	O
less	O
prone	O
to	O
collapsing	O
on	O
itself	O
.	O

As	O
the	O
E6	B-GP
protein	I-GP
is	O
predicted	O
to	O
be	O
highly	O
flexible	O
,	O
this	O
structure	O
is	O
an	O
approximation	O
of	O
a	O
more	O
open	O
state	O
of	O
the	O
protein	O
.	O

Supporting	O
Information	O

Sequences	O
of	O
primers	O
and	O
their	O
annealing	O
temperatures	O
(	O
Ta	O
)	O
used	O
in	O
this	O
study	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Summary	O
of	O
the	O
apparent	O
Kd	O
and	O
Bmax	O
values	O
of	O
CAF	O
-	O
25	O
,	O
-	O
26	O
,	O
-	O
27	O
and	O
CAF	O
-	O
40	O
with	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
and	O
mutant	O
proteins	O
determined	O
by	O
thermal	O
stability	O
assay	O
.	O

The	O
p53	B-GP
column	O
summarizes	O
the	O
in	O
vitro	O
degradation	O
activity	O
of	O
these	O
proteins	O
.	O

Fit	O
comparison	O
:(*)	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
wild	O
-	O
type	O
(	O
WT	O
)	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Characterization	O
of	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
and	O
mutant	O
proteins	O
and	O
MD	O
simulations	O
.	O

(	O
A	O
)	O
Analysis	O
of	O
p53	B-GP
in	O
vitro	O
degradation	O
activity	O
of	O
wild	O
-	O
type	O
MBP	B-GP
-	O
E6	B-GP
in	O
response	O
to	O
concentrations	O
of	O
CAF	O
-	O
26	O
by	O
western	O
blotting	O
.	O

p53	B-GP
and	O
MBP	B-GP
-	O
E6	B-GP
proteins	I-GP
were	O
analyzed	O
by	O
blotting	O
with	O
anti	O
-	O
p53	B-GP
and	O
anti	O
-	O
E6	B-GP
,	O
respectively	O
.	O

(	O
B	O
)	O
MD	O
simulations	O
of	O
CAF	O
-	O
25	O
and	O
(	O
C	O
)	O
CAF	O
-	O
40	O
with	O
E6	B-GP
protein	I-GP
(	O
PDB	O
ID	O
:	O
4GIZ	O
).	O

(	O
E	O
)	O
Raw	O
fluorescence	O
melt	O
curves	O
of	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
mutants	O
(	O
R10A	O
,	O
R55A	O
,	O
R102A	O
,	O
R131A	O
)	O
analyzed	O
using	O
the	O
TSA	O
.	O

(	O
F	O
)	O
Analysis	O
of	O
p53	B-GP
in	O
vitro	O
degradation	O
activity	O
of	O
MBP	B-GP
-	O
E6	B-GP
wild	O
-	O
type	O
and	O
R102A	O
proteins	O
after	O
3h	O
incubation	O
.	O

p53	B-GP
and	O
MBP	B-GP
-	O
E6	B-GP
(	O
WT	O
,	O
R102A	O
)	O
proteins	O
were	O
analyzed	O
by	O
blotting	O
with	O
anti	O
-	O
p53	B-GP
and	O
anti	O
-	O
E6	B-GP
,	O
respectively	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

ΔTM	O
profile	O
of	O
MBP	B-GP
-	O
E6	B-GP
mutants	O
in	O
response	O
to	O
CAF	O
-	O
25	O
.	O

ΔTM	O
changes	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
MBP	B-GP
-	O
E6	B-GP
and	O
(	O
A	O
)	O
R10A	O
,	O
(	O
B	O
)	O
L50G	O
,	O
(	O
C	O
)	O
R55A	O
,	O
and	O
(	O
D	O
)	O
R102A	O
mutant	O
proteins	O
in	O
response	O
to	O
increasing	O
concentrations	O
with	O
CAF	O
-	O
25	O
subtracted	O
by	O
the	O
DMSO	O
control	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

ΔTM	O
profile	O
of	O
MBP	B-GP
-	O
E6	B-GP
mutants	O
in	O
response	O
to	O
CAF	O
-	O
26	O
.	O

ΔTM	O
changes	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
MBP	B-GP
-	O
E6	B-GP
and	O
(	O
A	O
)	O
R10A	O
,	O
(	O
B	O
)	O
L50G	O
,	O
(	O
C	O
)	O
R55A	O
,	O
and	O
(	O
D	O
)	O
R102A	O
mutant	O
proteins	O
in	O
response	O
to	O
increasing	O
concentrations	O
with	O
CAF	O
-	O
26	O
over	O
DMSO	O
control	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
compared	O
to	O
WT	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

ΔTM	O
profile	O
of	O
MBP	B-GP
-	O
E6	B-GP
mutants	O
in	O
response	O
to	O
CAF	O
-	O
27	O
.	O

ΔTM	O
changes	O
of	O
wild	O
type	O
(	O
WT	O
)	O
MBP	B-GP
-	O
E6	B-GP
and	O
(	O
A	O
)	O
R10A	O
,	O
(	O
B	O
)	O
L50G	O
,	O
(	O
C	O
)	O
R55A	O
,	O
(	O
D	O
)	O
R102A	O
and	O
(	O
E	O
)	O
R131A	O
mutant	O
proteins	O
in	O
response	O
to	O
increasing	O
concentrations	O
with	O
CAF	O
-	O
27	O
over	O
DMSO	O
control	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
compared	O
to	O
WT	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

ΔTM	O
profile	O
of	O
MBP	B-GP
-	O
E6	B-GP
mutants	O
in	O
response	O
to	O
CAF	O
-	O
40	O
.	O

ΔTM	O
changes	O
of	O
wild	O
type	O
(	O
WT	O
)	O
MBP	B-GP
-	O
E6	B-GP
and	O
(	O
A	O
)	O
R10A	O
,	O
(	O
B	O
)	O
L50G	O
,	O
(	O
C	O
)	O
R55A	O
,	O
(	O
D	O
)	O
R102A	O
and	O
(	O
E	O
)	O
R131A	O
mutant	O
proteins	O
in	O
response	O
to	O
increasing	O
concentrations	O
with	O
CAF	O
-	O
40	O
over	O
DMSO	O
control	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
compared	O
to	O
WT	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
CAF	O
-	O
25	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
mutants	O
.	O

MD	O
simulations	O
show	O
that	O
R102	O
and	O
R131	O
are	O
major	O
contributors	O
to	O
the	O
interaction	O
of	O
CAF	O
-	O
25	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
.	O

Panels	O
A	O
-	O
E	O
showcase	O
the	O
interactions	O
of	O
various	O
E6	B-GP
residues	O
with	O
CAF	O
-	O
25	O
in	O
each	O
respective	O
mutant	O
.	O

Of	O
particular	O
interest	O
are	O
the	O
residues	O
R102	O
and	O
R131	O
.	O

These	O
two	O
amino	O
acids	O
are	O
main	O
contributors	O
to	O
the	O
interaction	O
between	O
ligand	O
and	O
protein	O
.	O

(	O
E	O
)	O
With	O
the	O
loss	O
of	O
R131	O
,	O
R102	O
becomes	O
a	O
main	O
driving	O
force	O
in	O
the	O
protein	O
–	O
CAF	O
-	O
25	O
interaction	O
.	O

(	O
D	O
)	O
When	O
R102	O
is	O
lost	O
,	O
R129	O
,	O
which	O
has	O
minimal	O
contact	O
with	O
the	O
ligand	O
(	O
A	O
,	O
B	O
,	O
C	O
,	O
E	O
),	O
is	O
shifted	O
to	O
more	O
efficiently	O
interact	O
and	O
results	O
in	O
a	O
change	O
in	O
the	O
shape	O
of	O
the	O
protein	O
(	O
F	O
).	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
CAF	O
-	O
40	O
with	O
HPV	B-OG
-	I-OG
16	I-OG
E6	B-GP
mutants	O
.	O

Panels	O
A	O
-	O
E	O
highlight	O
the	O
interactions	O
of	O
various	O
E6	B-GP
residues	O
with	O
CAF	O
-	O
40	O
in	O
each	O
respective	O
mutant	O
.	O

The	O
mutations	O
of	O
R131	O
and	O
R102	O
cause	O
other	O
rim	O
arginines	O
to	O
move	O
in	O
and	O
aid	O
with	O
the	O
ligand	O
-	O
protein	O
interaction	O
(	O
D	O
,	O
E	O
).	O

Specifically	O
,	O
R102A	O
causes	O
a	O
change	O
in	O
the	O
protein	O
shape	O
to	O
accommodate	O
a	O
more	O
efficient	O
interaction	O
between	O
R129	O
and	O
CAF	O
-	O
40	O
(	O
D	O
,	O
F	O
).	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

